

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand: A Cluster Randomized Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-036963
Article Type:	Protocol
Date Submitted by the Author:	13-Jan-2020
Complete List of Authors:	<p>Angkurawaranon, Chaisiri; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Papachristou Nadal, Iliatha; London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health Mallinson, Poppy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology Pinyopornpanish, Kanokporn; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Quansri, Orawan; Mahidol University Rerkasem, Kittipan ; Chiang Mai University, Department of Surgery, Faculty of Medicine, Chiang Mai University; Chiang Mai University, Research Institute for Health Sciences Srivanichakorn, Supattra; Royal Thai Government Ministry of Public Health Techakehakij, Win; Lampang Hospital Wichit, Nutchath; Surat Thani Rajabhat University Pateekhum, Chanapat; Chiang Mai University Hashmi, Ahmar; Chiang Mai University, Department of Family Medicine Hanson, Kara; London School of Hygiene and Tropical Medicine Khunti, Kamlesh; University of Leicester, Department of Health Sciences Kinra, Sanjay; London School of Hygiene and Tropical Medicine</p>
Keywords:	DIABETES & ENDOCRINOLOGY, EDUCATION & TRAINING (see Medical Education & Training), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand: A**
4
5 **Cluster Randomized Trial**
6

7 Chaisiri Angkurawaranon^{1*}, Iliatha Papachristou Nadal^{2,11}, Poppy Mallinson², Kanokporn
8 Pinyopornpanish¹, Orawan Quansri³, Kittipan Rerkasem^{4,5}, Supattra Srivanichakorn⁶, Win
9 Techakehakij⁷, Nutchath Wichit⁸, Chanapat Pateekhum¹, Ahmar Hashmi¹, Kara Hanson⁹,
10 Kamlesh Khunti¹⁰, Sanjay Kinra²
11
12
13
14
15

16
17 **Author affiliations**
18

19 ¹ Department of Family Medicine, Faculty of Medicine, Chiang Mai University
20

21 ² Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22 ² Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

47
48
49
50
51
52
53
54
55
56
57
58
59
60

48
49
50
51
52
53
54
55
56
57
58
59
60

49
50
51
52
53
54
55
56
57
58
59
60

50
51
52
53
54
55
56
57
58
59
60

51
52
53
54
55
56
57
58
59
60

52
53
54
55
56
57
58
59
60

53
54
55
56
57
58
59
60

54
55
56
57
58
59
60

55
56
57
58
59
60

56
57
58
59
60

57
58
59
60

58
59
60

59
60

Corresponding author: Chaisiri Angkurawaranon, Department of Family Medicine, Faculty of
Medicine, Chiang Mai University, email: chaisiri.a@cmu.ac.th

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **ABSTRACT**

2 **Introduction** Type 2 diabetes mellitus is amongst the foremost health challenges facing policy
3 makers in Thailand as its prevalence has more than tripled over the last two decades, accounting
4 for considerable death, disability and healthcare expenditure. Diabetes Self-Management
5 Education (DSME) programmes shows promise in improving diabetes outcomes, but this is not
6 routinely utilised in Thailand. This study aims to test a culturally tailored DMSE model in
7 Thailand, using a 3-arm cluster randomised controlled trial comparing a nurse-led model, a peer-
8 assisted model, and standard care. We will test which model is effective and cost effective to
9 improve cardiovascular risk and control of blood glucose among people with diabetes.

10
11 **Methods and analysis** 21 primary care units in northern Thailand will be randomised to one of
12 three interventions, enrolling a total of 693 patients. The primary care units will be randomised
13 (1:1:1) to participate in a culturally-tailored DSME intervention for 12 months. The 3-arm trial
14 design will compare effectiveness of nurse-led, peer-assisted (Thai village health volunteers) and
15 standard care. The primary trial outcome is glycaemic control. A process evaluation and cost
16 effectiveness evaluation will be conducted to produce policy relevant guidance for the Thai
17 Ministry of Public Health. The planned trial period will start in January 2020 and finish October
18 2021.

19
20 **Ethics and dissemination** Ethical approval was submitted in Thailand and the UK. We will
21 share our study data with other researchers, advertising via our publications and web presence. In
22 particular, we are committed to sharing our findings and data with academic audiences in
23 Thailand and other low- and middle-income countries.

1
2
3 24 **Trial registration number:**
4

5 25 ClinicalTrials.gov ID NCT03938233
6
7

8 26 **Strengths and limitation of this study**
9

- 10 27 • A three-arm cluster randomized control trial to evaluate clinical and cost-effectiveness of
11
12 28 a culturally tailored DSME under two alternative modes of delivery (nurse-led and peer-
13
14 29 assisted) will provide policy makers with options for scalability.
15
16
17 30 • A culturally-tailored DSME programme has been developed with input from stakeholders
18
19 31 (policy makers, clinicians, nurses, village health volunteers and people with diabetes).
20
21
22 32 • A series of short films has been developed to introduce key topics, as there is increasing
23
24 33 recognition that films are a highly efficient medium for communicating information,
25
26 34 particularly in low literacy settings
27
28
29
30
31
32
33
34
35
36
37

38 INTRODUCTION

39 Type 2 diabetes mellitus (hereto referred to as diabetes) is amongst the
40 foremost health challenges facing policy makers in Thailand. Its prevalence has more than tripled
41 over the last two decades to an estimated 4 million adults (age adjusted prevalence 7.1%) living
42 with diabetes in 2015.^{1,2} Diabetes is associated with several macrovascular (e.g. ischaemic heart
43 disease) and microvascular complications (e.g. nephropathy, retinopathy, neuropathy, and foot
44 disease), which primarily account for the considerable death and disability (of which diabetes is
45 the 5th leading cause in Thailand). In addition, diabetes in Thailand causes two-fold increase in
46 healthcare expenditure and significant loss of economic productivity—of both diabetic patients
47 and their carers.¹⁻⁴

48 The complications of diabetes can be largely prevented or delayed through lifestyle change
49 and medication when necessary, and regular screening for early detection and management of
50 complications to control risk factors such as blood glucose, lipids and blood pressure.^{3,4} Under
51 Thailand's universal health coverage, nearly everyone diagnosed with
52 diabetes receives timely medical care (>97%) and has access to screening. Yet, surveys suggest
53 that only about half of the people with diabetes achieve optimal control of risk factors or receive
54 annual screening for microvascular complications (53-60%).^{1,5} Limited data support a lack
55 of engagement and self-management skills among those diagnosed with diabetes as the main
56 underlying reasons for this.⁶

57 Successful management of diabetes involves a considerable degree of self-management. People
58 with diabetes need to adhere to multiple behaviours, including healthy
59 lifestyles, regular monitoring and medication, problem-solving and healthy coping. In this, they
60 are greatly supported by diabetes self-management education (DSME), defined as 'a
61 collaborative and ongoing process intended to facilitate the development of knowledge, skills,

1
2
3 62 and abilities that are required for successful self-management of diabetes'.⁷ Evidence from over
4
5 63 100 studies, including many randomised controlled trials, conducted predominantly in high-
6
7 64 income countries, suggests that DSME programs are associated with improvements in a range of
8
9 65 behavioural (knowledge, behaviours, self-efficacy, psychosocial) and clinical (physiological risk
10
11 66 factors, screening for complications, quality of life) outcomes,^{8,9} and are also cost-
12
13 67 effective.¹⁰ Therefore, DSME programs are recommended by most clinical guidelines.⁷
14
15 68 However, there is considerable heterogeneity in the effectiveness of DSME programmes^{8,9}.
16
17 69 Programmes that are more effective usually offer more than 10 hours of contact between trainers
18
19 70 and patients, incorporate behavioural approaches and provide longer-term support mechanisms.
20
21 71 However, providing intensive and sustained support has cost implications, resulting in ongoing
22
23 72 efforts to identify more cost-efficient ways to deliver DSME, notably through use of lay health
24
25 73 workers or peer educators, such as Thai village health volunteers (VHV).
26
27 74 Peers can support sustained changes in complex health behaviours by providing assistance in
28
29 75 daily management, social and emotional support, linkage to clinical care, and ongoing
30
31 76 availability of support.^{11,12} Unlike the educational/psychological framework of professional
32
33 77 support, peer support operates on a social support framework. Although traditionally restricted to
34
35 78 those with experience of disease, the definition of peers has been expanded to include other non-
36
37 79 professionals with a close relationship with the community (e.g. VHV).¹³ However, despite
38
39 80 widespread interest, empirical data on effectiveness of peers in supporting behaviour change in
40
41 81 chronic diseases, including diabetes, is limited and inconsistent.^{11,12} In an earlier review, the
42
43 82 World Health Organisation did not find sufficient evidence to recommend peer
44
45 83 support programs as a policy option for diabetes management in LMICs.¹⁴ Whereas many studies
46
47 84 on the effectiveness of DSME programmes come from high-income countries (HIC), there is a
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 85 dearth of data from LMIC settings on cost-effectiveness, acceptability and potential adverse
4
5 86 consequences of peer support programmes, as well as optimal strategies for mobilising and
6
7 87 integrating peers in diabetes care pathways^{12,17-18}.

8 88 In the Thai healthcare system, structured DSME is not routinely available. While several small-
9
10 89 scale studies from Thailand have demonstrated that DSME can strengthen self-management of
11
12 90 diabetes, negative perceptions of educational programs and concerns about the burden on
13
14 91 existing staff time and costs, have so far prevented the introduction of DSME.^{1,18} However,
15
16 92 recent policy developments in Thailand are supportive of DSME introduction, if a scalable
17
18 93 model can be found. We therefore hypothesise that a nurse-led and/or peer-assisted model for
19
20 94 DSME delivery will be effective in improving blood glucose among people with diabetes, with
21
22 95 the peer-assisted model being the more scalable option for the Thai healthcare system. We
23
24 96 propose to evaluate this through a 3-arm cluster randomised controlled trial.
25
26
27
28
29
30
31
32

33 98 **METHODS AND ANALYSIS**

34 35 99 **Study design**

36
37 100 This study is an MRC complex intervention¹⁹ 3-arm cluster randomised controlled trial. Primary
38
39 101 care units will be randomised for patients to receiving either the nurse-led or peer-assisted
40
41 102 DSME intervention or standard care (brief education session by a nurse). Assessments will be
42
43 103 undertaken at baseline, 6- and 12-month follow up. A process and cost-effective evaluation will
44
45 104 also be conducted.
46
47
48
49
50

51 106 **Randomisation**

52
53
54
55
56
57
58
59
60

1
2
3 107 Twenty-one primary care units will be randomised to provide one of three interventions: (1)
4
5 108 nurse-led DSME; (2) nurse-led DSME with peer assistance (provided by Thai village health
6
7 109 volunteers, VHVs); or (3) standard care (brief education session by a nurse), resulting in seven
8
9
10 110 primary care units in each arm of the study. All primary care units follow protocols for diabetes
11
12 111 management as outlined by national guidelines. Randomisation will minimise any variation in
13
14
15 112 practice between the different primary care units.
16
17 113

19 114 **Sample size calculation**

21 115 The intervention is powered to detect a clinically important difference of 0.6 units HbA1c (SD
22
23 116 1.5 units) between the control and intervention arms. Therefore, 693 participants are needed from
24
25
26 117 21 primary care units (7 in each trial arm arm) to achieve 80% power at 5% significance level,
27
28 118 assuming an intra-cluster correlation coefficient (ICC) between primary care units of 0.02 and
29
30
31 119 loss to follow-up rate of 20%^{20,21}.
32

35 121 **Participant Selection**

37 122 693 patients requiring a DSME intervention will be recruited from 21 primary care units in
38
39 123 Chiang Mai and Lampang provinces in northern Thailand. While diabetes is diagnosed at tertiary
40
41
42 124 hospitals, it is managed at the primary care unit health centres, which are served by a full-time
43
44
45 125 nurse (doctor visits weekly), and 10-15 village health volunteers (VHV) linking patients in the
46
47 126 community.
48

49 127 We will recruit all new referrals for diabetes management and patients with uncontrolled
50
51 128 diabetes diagnosed in the past 3 years at the 21 primary care units over a 9-month period
52
53
54
55
56
57
58
59

1
2
3 129 (N=693). Posters and information sheets will be used to provide necessary, trial-related
4
5 130 information to prospective participants.
6
7

8 131

9
10 132 Participants presenting to one of the 21 primary care units will be included if they are:
11

- 12 133 1. Over 18 years of age with a new referral for type 2 diabetes management;
13
14 134 2. Over 18 years of age with uncontrolled in diabetes (HbA1c>7 mg/dl) within the first
15
16 135 three years of diagnosis;
17
18 136 2. Willing and able to attend educational group meetings; and
19
20 137 3. Available for six and 12-month follow-up visits
21
22

23
24 138 Participants will be excluded if they:
25

- 26 139 1. Have advanced diabetic complications such as diabetic nephropathy, diabetic
27
28 140 retinopathy, or amputations; or if they are pregnant;
29
30 141 2. Have learning disabilities, dementia or active severe mental illness; or
31
32 142 3. Lack the capacity to give voluntary, informed consent.
33
34

35 143


36 37 144 **Informed consent**

38
39 145 Written informed consent will be obtained from all study participants in Thai before any study
40
41 146 procedures are undertaken including enrolment, intervention allocation, follow-up interviews and
42
43 147 blood draws. Local research assistants will explain the study to patients using the patient
44
45 148 information sheet. The right of the patient to refuse to participate without giving reasons will be
46
47 149 respected.
48
49

50
51 150
52
53
54
55
56
57
58
59
60

151

Figure 1: Trial flow diagram



152

153

154 Intervention description and delivery

155 The DSME programme has been developed using a structured process. This included a desk and
 156 literature review and focus groups with local nurses and village health volunteers to develop a
 157 paper prototype of the intervention, including a hypothesised pathway of action (e.g. common-
 158 sense model of illness, empowerment, discovery learning, social learning, and social support)
 159 and a training manual for nurses and VHVs. In addition, seven brief films (5-6 minutes long)
 160 have been developed and have been used to trigger discussions on key topic areas during DSME
 161 intervention meetings covering such topics as medical adherence, dietary recommendation,

1
2
3 162 physical activity and stress management. Films will be used in the intervention as they are
4
5 163 increasingly recognised as a highly effective medium for improved recall when communicating
6
7 164 large amounts of information, particularly in low literacy settings²². Films will be in the local
8
9 165 language and use local people.
10
11
12
13

14
15 167 The nurses and VHVs in the intervention arms will be trained to deliver the DSME programme
16
17 168 (at the community hospital or neighbourhoods as appropriate). The intervention will be piloted at
18
19 169 four community hospitals with four nurses and four VHVs who will be trained to deliver the
20
21 170 DSME programme to groups of 5-10 persons with diabetes. This will allow for refining the
22
23 171 intervention, ensuring data collection can be completed as specified, and to check our
24
25 172 assumptions and processes for the trial.
26
27
28
29

30
31 174 A process evaluation at the end of the study will aim to assess intervention delivery (fidelity,
32
33 175 dose and reach), clarify causal mechanisms (those hypothesised by theory of change developed
34
35 176 within the project or identify unexpected ones), and identify contextual factors (barriers,
36
37 177 facilitators) associated with variation in outcomes.²³ The process evaluation will consist of one-
38
39 178 to-one interviews with clinicians and policy makers and direct observations of patients. Data for
40
41 179 economic evaluation (resource usage and quality of life using EQ-5D²⁴) will be obtained
42
43 180 prospectively alongside the trial.
44
45
46

47 181

48 182 **Standard care**

49
50
51 183 Patients in the control group will receive standard care in the form a brief didactic educational
52
53 184 session at the time of diagnosis of diabetes²⁵.
54
55
56
57
58
59
60

1
2
3 **185 Study outcomes**
4

5 **186** The primary trial outcome of the intervention is a difference in trial arms at one-year follow-up
6
7
8 **187** in HbA1c. There is a growing recognition of the importance of combining tight glycaemic
9
10 **188** control with reduction in other cardiovascular risk factors for prevention of or reduction
11
12 **189** in complications.⁴
13

14 **190** The cardiovascular risk will be estimated by the Thai cardiovascular risk score model, which
15
16 **191** estimates the risk of dying from any cardiovascular disease over 10 years based on age, gender,
17
18 **192** smoking habits, total cholesterol and systolic blood pressure, as it has been calibrated for use in a
19
20 **193** Thai population.²⁶ Additional measures include biophysical data, psychosocial and lifestyle data
21
22 **194** and intervention related data, as described in Table 1.
23
24
25

26 **195**
27

28 **196 Table 1:** Primary and Secondary Outcome measures
29
30

Target domain	Measures or questionnaires
Cardiovascular risk assessment	<p data-bbox="540 1150 1419 1255">Haemoglobin A1c levels (HbA1c): HbA1c will measure the average blood glucose (sugar) levels months</p> <p data-bbox="540 1367 699 1402">Blood lipids</p> <p data-bbox="540 1444 846 1480">Body Mass Index; BMI</p> <p data-bbox="540 1522 808 1558">Waist circumference</p> <p data-bbox="540 1600 737 1635">Blood pressure</p>
Quality of life	<p data-bbox="540 1669 1398 1774">WHOQOL BREF- A 26 item questionnaire developed by WHO to assess quality of life in adults²⁷</p> <p data-bbox="540 1816 1393 1852">The European Quality of Life questionnaire; EuroQol EQ-5D 5L²⁴</p>

	EQ-5D is a quality of life measure that includes five quality of life questions on mobility, self-care, usual activity, pain, anxiety / depression and a scale of 0 to 100 on how the person is feeling on that day.
Depression	Hospital Anxiety and Depression Scale; HADS ²⁸ HADS measures depression and anxiety that will address psychological change with a scale from 0 to 3.
Stress	Perceived stress questionnaire; PSS ²⁹ PSS is a psychological instrument for measuring the perception of stress. Ten items with a scale from 1 to 4.
Physical activity	International Physical Activity Questionnaire; IPAQ ³⁰ Short form IPAQ is an assessment of physical activity comprising of seven questions. There are two forms of output from scoring the IPAQ. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). MET minutes represent the amount of energy expended carrying out physical activity.
Diabetes knowledge	Brief diabetes illness perception questionnaire; B-IPQ ³¹ .

	<p>B-IPQ has nine components of which the first five questions assess the cognitive representation of illness perception, two of the questions assess the emotional representation, one item assesses comprehensibility and one item on the root cause of the illness</p> <p>Diabetes Self-Management Education and Support; DMSES³².</p> <p>DMSES is one of the most widely used scale in measuring self-efficacy in type 2 diabetes management. The Thai-DMSES has twenty questions which has been demonstrated to have good psychometric properties³²</p> <p>Summary of Diabetes self-care activities questionnaire SDSCA³⁴</p> <p>SDSCA is a diabetes self-care activities questionnaire focusing on general diet, diabetes-specific diet, physical activity, blood-glucose testing, foot care, and smoking.</p>
<p>Satisfaction with intervention</p>	<p>Chronic Illness Resources survey (CIRS)³⁵</p> <p>CIRS is a questionnaire to represent patient's received support.</p> <p>Individual's support for behavioural-specific disease management is assessed: proximal support e.g. friend and family and distal factor e.g. neighbourhood or community.</p>
	<p>Modified Medical Interview Satisfaction scale (MISS-21)³⁶</p> <p>MISS-21 is a questionnaire to measure patient satisfaction with patient and health care professional communication/consultation.</p>

197

198 Data collection and follow-up

199 Each participant will be involved in the study for 12 months after taking consent and baseline
200 data. The trial is expected to start January 2020 and finish October 2021.

201

202 Data collection methods will include:

203 a) Questionnaires: Questionnaire data will be collected face-to-face by research assistants for the
204 full sample at baseline, 6 and 12 months at the community hospital where participants are
205 recruited (Table 1). A custom-designed form linked to Microsoft Access will be used to collect,
206 validate, verify, and store respondents' data where possible or else data will be collected via
207 paper forms and double-entered into the databases. All data files and databases will be password
208 protected.

209

210 b) Biological samples: Blood samples will be collected at baseline, 6 and 12 months, to measure
211 fasting blood glucose, HbA1c and lipids, coordinating where possible with the annual routine
212 tests offered to patients to reduce duplication. All blood samples will be administered from
213 participants by trained phlebotomists. Data will be linked to the participant information using a
214 unique respondent ID, which will be assigned to all study participants.

215

216 c) Interviews: During the delivery of the intervention, a process evaluation using a subset of
217 participants will be followed up using in-depth interviews and focus group discussions. These
218 will be audio-recorded. Data will be collected using a range of qualitative methods: a) one to
219 one interviews, and focus group discussions with nurses, health volunteers, people with diabetes
220 and their carers (5-10 focus groups, and 20 semi-structured interviews) and b) ethnography

1
2
3 221 through direct observations including video recordings of intervention delivery, and unstructured
4
5 222 interviews with clinical managers and policy makers. The data collected will be used to
6
7
8 223 capture the range of experiences of the intervention, and identify unanticipated pathways to
9
10 224 generate new theories as well as exploring the scalability of the intervention.
11

12 225

14 226 **Trial follow-up appointments**

16
17 227 The research team will hold weekly briefings with the study coordinators to generate a list of
18
19 228 priority areas and loss to follow-up participant lists. Arrangements to follow-up participants who
20
21 229 have not turned up for their appointment will be made, with attempts to contact participants
22
23
24 230 through SMS, phone calls, or house visits. Participants will be declared loss to follow-up if they
25
26 231 do not show for a month and are untraceable.
27

28 232

31 233 **Data management**

33
34 234 A data collection protocol will be developed, and the study coordinator in Thailand will provide
35
36 235 training to fieldworkers before data collection commences. Validation will be performed a
37
38 236 random sample of questionnaire data by crosschecking with clinic records. Any discrepancies
39
40
41 237 will be followed-up and addressed by field workers, re-contacting participants to clarify as
42
43 238 necessary. Quantitative data will be entered directly via a form with built-in data checks to
44
45 239 minimise transcription errors (or where necessary collected on paper and later double entered
46
47
48 240 into the electronic form). Post entry checks will be conducted using statistical software. All
49
50 241 hospital laboratories have their own internal quality assurance protocols and are also linked to a
51
52 242 national external quality assurance mechanism. Fieldworkers will be trained in qualitative
53
54
55 243 methods and an interview schedule will be devised.
56
57
58
59

1
2
3 2444
5 **245 Statistical analysis**6
7
8 **246 1. Quantitative analysis**

9
10 247 Available outcome data will be analysed on an intention-to-treat basis. Potential clustering of
11
12 248 outcomes at the level of community primary care units will be accounted for using mixed-effects
13
14 249 models. Adjustment for baseline imbalances in outcomes or relevant covariates will be
15
16 250 considered as appropriate.
17

18
19 25120
21 **252 2. Qualitative analysis**

22
23 253 Qualitative data from interviews, focus groups and direct observations be will transcribed and
24
25 254 analysed using NVivo software. The data will be analysed using a descriptive, phenomenological
26
27 255 approach to understand participants' experiences and interpret them within their respective
28
29 256 cultural contexts. Comparative analysis will compare and contrast these themes across
30
31 257 participants. Deviant cases will be actively sought throughout the analysis and emerging ideas
32
33 258 and themes modified in response. In addition, thematic analysis will be used to inform elements
34
35 259 of scalability and to produce a set of considerations in making decisions about the scalability of
36
37 260 the intervention.
38
39
40

41
42 26143
44 **262 ETHICS AND DISSEMINATION**

45
46 263 This study is to be conducted according to the international standards of Good Clinical Practice
47
48 264 (International Conference on Harmonization guidelines), Declaration of Helsinki, and
49
50 265 International Ethical Guidelines for Biomedical Research Involving Human Subjects, applicable
51
52 266 national government regulations, and institutional research policies and procedures. All
53
54
55
56
57
58
59

1
2
3 267 investigators will receive GCP training at the onset of the study. Ethical approvals will be sought
4
5 268 prior to commencement of the project from Thailand's Central Research Ethics Committee and
6
7
8 269 the London School of Hygiene & Tropical Medicine. The study protocol, informed consent form,
9
10 270 participant's information sheet and other relevant information has been submitted to and
11
12 271 approved by Chiang Mai University and local Ethics Committee. Any future amendments of the
13
14
15 272 protocol shall be submitted to and approved by the Institutional Review Board (IRB) before
16
17 273 implementation
18
19
20 274

21 275 **Trial monitoring and oversight**

22
23
24 276 The role of the Trial Steering Committee (TSC) is to provide overall supervision of the trial. The
25
26 277 TSC will meet every six months. The TSC will include experts in the field of DSME, health
27
28 278 psychology and clinical trials, as well as an independent Chair. In addition, we will have patient
29
30 279 and carer representatives and policy representation.
31
32
33
34 280

35 36 281 **Dissemination**

37
38
39 282 Expected output and impact research findings will be disseminated to scientific audiences at
40
41 283 major conferences and published in high-impact open-access scientific journals; planned
42
43 284 publications include those on intervention development, primary trial results, and process
44
45 285 evaluation, and health systems analysis, at a minimum. This study is expected to have a major
46
47 286 policy impact due to the close involvement of a key policy maker in the project. Towards the end
48
49
50 287 of the study a dedicated workshop will be held with key governmental stakeholders to
51
52 288 disseminate the recommended model for DSME implementation in Thailand and encourage
53
54
55 289 inclusion of a large-scale scientific evaluation into any national implementation of the scheme.
56
57
58
59

1
2
3 290
4
5 291 **Contributors:** CA, SS, OQ, PM, SK were involved in conception and trial design. CA, KP, PM
6
7 292 and SK wrote the first draft of the trial design proposal. KR, WT, KH, KK were involved in
8
9 293 critical revision of the trial design proposal. All authors contributed to finalising the trial
10
11 294 protocol. CA, KP, IP, CP, AH, NW were involved with preparation of the manuscript for
12
13 295 submission. All authors reviewed the manuscript and approved the manuscript for publication.
14
15
16
17 296

19 297 **Funding**

20
21 298 This study is supported by UK Medical Research Council (MRC) grant number
22
23 299 [MR/R020876/1] and the Thailand Research Fund (TRF) grant number [DBG6180007].
24
25

26 300

28 301 **Data availability**

29
30 302 Data will be shared upon reasonable request
31
32

33 303

35 304 **Patient and Public Involvement**

36
37 305 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or
38
39 306 dissemination plans of our research
40
41

42 307

44 308 **Trial sponsor**

45
46 309 This study is sponsored by London School of Hygiene & Tropical Medicine, Keppel Street,
47
48 310 London WC1E 7HT, UK [16113].
49
50

51 311 **Competing interests**

52
53 312 None declared
54
55
56
57
58
59
60

1
2
3 313 **Ethics approval**
4

5 314 The study has been approved by the Chiang Mai University Research Ethics Committee
6
7 [326/2018] and the London School of Hygiene & Tropical Medicine [16113/RR/12850].
8
9

10 316

11
12 317 **REFERENCES**
13

- 14 318 1. Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature
15
16 review of the burden, costs, and outcomes. *Glob Health* 2013; 9: 11.
17 319
18
19 320 2. International Diabetes Federation. *IDF Diabetes Atlas Seventh Edition*. 2015.
20
21 321 3. Effect of intensive blood-glucose control with metformin on complications in
22
23 overweight patients with type 2 diabetes (UKPDS 34). *The Lancet* 1998; 352: 854–
24 322 65.
25
26 323
27
28 324 4. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial
29
30 intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J*
31 325 *Med* 2003; 348: 383–93.
32
33 326
34
35 327 5. Rangsin R. An assessment of quality of care among patients diagnosed with type 2
36
37 diabetes and hypertension visiting hospitals of ministry of public health and Bangkok
38 328 Metropolitan Administration in Thailand. 2012.
39
40 329
41
42 330 6. Auemaneekul N, Chandanasotthi P, Rawiworrakul T, et al. Community Partnership,
43
44 Contextbased Intervention and Diabetes Control in Thailand. *J Public Health* 2016;
45 331 46: 236–47.
46
47 332
48
49 333 7. Haas L, Maryniuk M, Beck J, et al. National standards for diabetes self-management
50
51 education and support. *Diabetes Educ* 2012; 38: 619–629.
52 334
53
54
55
56
57
58
59
60

- 1
2
3 335 8. Chryala CA, et al. Diabetes self-management education for adults with type 2
4
5 336 diabetes mellitus: A systematic review of the effect on glyceemic control. Patient
6
7 Educ Couns 2016; 99: 926–43.
8 337
9
10 338 9. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral Programmes for Type 2 Diabetes
11
12 339 Mellitus: A Systematic Review and Network Meta-analysis. Ann Intern Med 2015;
13
14 340 163: 848.
15
16 341 10. Doyle G, O'Donnell S, Quigley E, et al. Patient level cost of diabetes self-
17
18 342 management education programmes: an international evaluation. BMJ Open 2017; 7:
19
20 343 e013805.
21
22 344 11. Fisher EB, Boothroyd RI, Elstad EA, et al. Peer support of complex health behaviors
23
24 345 in prevention and disease management with special reference to diabetes: systematic
25
26 346 reviews. Clin Diabetes Endocrinol 2017; 3. DOI:10.1186/s40842-017-0042-3.
27
28 347 12. Dale JR, Williams SM, Bowyer V. What is the effect of peer support on diabetes
29
30 348 outcomes in adults? A systematic review. Diabet Med 2012; 29: 1361–77.
31
32 349
33 350 13. Norris SL, Chowdhury FM, Van Le K, et al. Effectiveness of community health
34
35 351 workers in the care of persons with diabetes. Diabet Med J Br Diabet Assoc 2006;
36
37 352 23: 544–56.
38
39 353 14. World Health Organization. Peer support programmes in diabetes: Report of a WHO
40
41 354 consultation 5-7 November 2007. Geneva, Switzerland: WHO, 2008.
42
43 355 15. Fisher EB, Boothroyd RI, Coufal MM, et al. Peer Support For Self-Management Of
44
45 356 Diabetes Improved Outcomes In International Settings. Health Aff (Millwood) 2012;
46
47 357 31: 130–9.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 358 16. Trento M, Gamba S, Gentile L, et al. Rethink Organization to iMprove Education
4
5 359 and Outcomes (ROME0): A multicenter randomized trial of lifestyle intervention by
6
7 360 group care to manage type 2 diabetes. *Diabetes Care* 2010; 33: 745–7.
8
9
10 361 17. Werfalli M, Raubenheimer P, Engel M, et al. Effectiveness of community-based
11
12 362 peer-led diabetes self-management programmemes (COMP-DSMP) for improving
13
14 363 clinical outcomes and quality of life of adults with diabetes in primary care settings
15
16 364 in low and middle-income countries (LMIC): a systematic review and meta-analysis.
17
18 365 *BMJ Open* 2015; 5: e007635.
19
20
21 366 18. Keeratiyutawong P, Hanucharurnkl S, Melkus G, Vorapongsathon OPT.
22
23 367 Effectiveness of a self-management programme for Thais with type 2 diabetes. *Thai*
24
25 368 *J Nurs Res* 2006; 10: 85–97.
26
27
28 369 19. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
29
30 370 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*
31
32 371 2008; a1655.
33
34
35 372 20. Wattana C, Srisuphan W, Pothiban L, Upchurch SL. Effects of a diabetes self-
36
37 373 management programme on glycaemic control, coronary heart disease risk, and
38
39 374 quality of life among Thai patients with type 2 diabetes. *Nurs Health Sci* 2007; 9:
40
41 375 135–41.
42
43
44 376 21. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self-
45
46 377 management programme (DESMOND) for people with newly diagnosed type 2
47
48 378 diabetes mellitus: Three-year follow-up of a cluster randomised controlled trial in
49
50 379 primary care. *BMJ* 2012; 344: e2333–e2333.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 380 22. Tuong W, Larsen ER, Armstrong AW. Videos to influence: a systematic review of
4
5 381 effectiveness of video-based education in modifying health behaviors. *J Behav Med*
6
7 382 2014; 37: 218–33.
- 8
9
10 383 23. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions:
11
12 384 Medical Research Council guidance. *BMJ* 2015; 350: h1258–h1258. 25Mangham LJ,
13
14 385 Hanson K. Scaling up in international health: what are the key issues? *Health Policy*
15
16 386 *Plan* 2010; 25: 85–96.
- 17
18
19 387 24. Kimman M, et al. Validity of the Thai EQ-5D in an occupational population in
20
21 388 Thailand. *Qual Life Res* 2013 Aug; 22(6):1499-506.
- 22
23
24 389 25. Clinical Practice Guidelines for Diabetes. Diabetes Association of Thailand, 2017.
25
26 390 (<https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443->
27
28 391 [guideline-diabetes-care-2017](https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-guideline-diabetes-care-2017))
- 29
30
31 392 26. Aekplakorn A, Bunnag P, Woodward M. et al. Risk Score for Predicting Incident
32
33 393 Diabetes in the Thai Population. *Diabetes Care* 2006 Aug; 29(8):1872-1877
- 34
35 394 27. Mahatnirunkul S. et al. Comparison of the WHOQOL-100 and the WHOQOL-
36
37 395 BREF. *Journal of Mental Health of Thailand* 1998; 5(3).
- 38
39
40 396 28. Nilchaikovit T. et al. Development of Thai version of Hospital Anxiety and
41
42 397 Depression Scale in cancer patients. *J Psychiatr Assoc Thailand* 1996; 41(1):18-30.
- 43
44 398 29. Wongpakaran N, Wongpakaran T. The Thai version of the PSS-10: An investigation
45
46 399 of its psychometric properties. *BioPsychoSocial Medicine* 2010: 4:6
- 47
48
49 400 30. Rattanawiwatpong P, et al. Validity and reliability of the Thai version of Short
50
51 401 Format International Physical Activity Questionnaire (IPAQ). *J Thai Rehabil* 2006;
52
53 402 16(3):147-160.
- 54
55
56
57
58
59
60

- 1
2
3 403 31. Leelacharas S, et al. Illness perceptions, lifestyle behaviours, social support and
4
5 404 cardiovascular risks in people with Hypertension in Urban and Rural Areas of
6
7 405 Thailand. *Pacific Rim Int J Nur Res* 2015; 19
8
9
10 406 32. Lamsumang, W. The development of the Thai version of the diabetes management
11
12 407 self-efficacy scale (T-DMSES) for older adults with type 2 diabetes. State University
13
14 408 of New York at Buffalo, New York; 2009.
15
16
17 409 33. Sangruangake M, Jirapornkul C, Hurst C. Psychometric Properties of Diabetes
18
19 410 Management Self-Efficacy in Thai Type 2 Diabetes Mellitus Patients: A Multicenter
20
21 411 Study. *Int J Endocrinol*. 2017;2017:2503156. doi:10.1155/2017/2503156)
22
23
24 412 34. Keeratiyatawong, P, Hanucharumkul, S., Melkus, G. D. E., Panpakdee, O.,
25
26 413 Vorapongsathorn T. Effectiveness of a self-management programme for Thais with
27
28 414 type 2 diabetes. *Thai J Nurse Res*. 2006; 10: 85-97
29
30
31 415 35. Manit A, et al. Development of needs and resources for self-management assessment
32
33 416 instrument in Thais with type 2 diabetes: Cross-cultural adaptation. *J Med Assoc*
34
35 417 *Thai* 2011; Vol. 94 No. 11.
36
37
38 418 36. Meakin R and Weinman J. The 'Medical Interview Satisfaction Scale' (MISS-21)
39
40 419 adapted for British general practice. *Family Practice* 2002; 19:257–263.
41
42
43 420




Figure 1: Trial flow diagram

27x20mm (600 x 600 DPI)

BMJ Open

A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand (DSME-T): A Cluster Randomized Trial Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-036963.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Jun-2020
Complete List of Authors:	Angkurawaranon, Chaisiri; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Papachristou Nadal, Iliatha; London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health Mallinson, Poppy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology Pinyopornpanish, Kanokporn; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Quansri, Orawan; Mahidol University Rerkasem, Kittipan ; Chiang Mai University, Department of Surgery, Faculty of Medicine, Chiang Mai University; Chiang Mai University, Research Institute for Health Sciences Srivanchakorn, Supattra; Royal Thai Government Ministry of Public Health Techakehakij, Win; Lampang Hospital Wichit, Nutchath; Surat Thani Rajabhat University Pateekhum, Chanapat; Chiang Mai University Hashmi, Ahmar; Chiang Mai University, Department of Family Medicine Hanson, Kara; London School of Hygiene and Tropical Medicine Khunti, Kamlesh; University of Leicester, Department of Health Sciences Kinra, Sanjay; London School of Hygiene and Tropical Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Evidence based practice, Diabetes and endocrinology, General practice / Family practice
Keywords:	DIABETES & ENDOCRINOLOGY, EDUCATION & TRAINING (see Medical Education & Training), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand**
4
5 **(DSME-T): A Cluster Randomized Trial Study Protocol**
6

7 Chaisiri Angkurawaranon^{1*}, Iliatha Papachristou Nadal^{2,3}, Poppy Mallinson², Kanokporn
8 Pinyopornpanish¹, Orawan Quansri⁴, Kittipan Rerkasem^{5,6}, Supattra Srivanichakorn⁷, Win
9 Techakehakij⁸, Nutchath Wichit⁹, Chanapat Pateekhum¹, Ahmar Hashmi¹, Kara Hanson¹⁰,
10 Kamlesh Khunti¹¹, Sanjay Kinra²
11
12
13
14
15

16
17 **Author affiliations**
18

19 ¹ Department of Family Medicine, Faculty of Medicine, Chiang Mai University
20

21 ² Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
22 Medicine
23
24

25 ³ Psychological Medicines, King's College London
26

27 ⁴ ASEAN Institute for Health Development, Mahidol University
28

29 ⁵ Department of Surgery, Faculty of Medicine, Chiang Mai University
30

31 ⁶ NCD Centre of Excellence, Research Institute for Health Sciences, Chiang Mai University
32

33 ⁷ Department of Disease Control, Ministry of Public Health
34

35 ⁸ Department of Social Medicine, Lampang Hospital
36

37 ⁹ Faculty of Nursing, Suratthani Rajabhat University
38

39 ¹⁰ Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine
40

41 ¹¹ Diabetes Research Center, University of Leicester
42
43
44
45
46
47
48

49 Corresponding author: Chaisiri Angkurawaranon, Department of Family Medicine, Faculty of
50 Medicine, Chiang Mai University, email: chaisiri.a@cmu.ac.th
51
52
53
54
55
56
57
58

1 **ABSTRACT**

2 **Introduction** Type 2 diabetes mellitus is amongst the foremost health challenges facing policy
3 makers in Thailand as its prevalence has more than tripled over the last two decades, accounting
4 for considerable death, disability and healthcare expenditure. Diabetes Self-Management
5 Education (DSME) programmes show promise in improving diabetes outcomes, but this is not
6 routinely utilised in Thailand. This study aims to test a culturally-tailored DSME model in
7 Thailand, using a 3-arm cluster randomised controlled trial comparing a nurse-led model, a peer-
8 assisted model, and standard care. We will test which model is effective and cost effective to
9 improve cardiovascular risk and control of blood glucose among people with diabetes.

10
11 **Methods and analysis** 21 primary care units in northern Thailand will be randomised to one of
12 three interventions, enrolling a total of 693 patients. The primary care units will be randomised
13 (1:1:1) to participate in a culturally-tailored DSME intervention for 12 months. The three-arm
14 trial design will compare effectiveness of nurse-led, peer-assisted (Thai village health volunteers)
15 and standard care. The primary trial outcomes are changes in haemoglobin A1c and
16 cardiovascular risk score. A process evaluation and cost effectiveness evaluation will be
17 conducted to produce policy relevant guidance for the Thai Ministry of Public Health. The
18 planned trial period will start in January 2020 and finish October 2021.

19
20 **Ethics and dissemination** Ethical approval has been obtained from Thailand and the UK. We
21 will share our study data with other researchers, advertising via our publications and web
22 presence. In particular, we are committed to sharing our findings and data with academic
23 audiences in Thailand and other low- and middle-income countries.

1
2
3 24 **Trial registration number:**
4

5 25 ClinicalTrials.gov ID NCT03938233
6
7

8 26 **Strengths and limitation of this study**
9

- 10 27 • A three-arm cluster randomized control trial to evaluate clinical and cost-effectiveness of
11
12 28 a culturally tailored DSME under two alternative modes of delivery (nurse-led and peer-
13
14 29 assisted) will provide policy makers with options for scalability.
15
16
17 30 • A culturally-tailored DSME programme has been developed with input from stakeholders
18
19 31 (policy makers, clinicians, nurses, village health volunteers and people with diabetes).
20
21
22 32 • A series of short films has been developed to introduce key topics, as there is increasing
23
24 33 recognition that films are a highly efficient medium for communicating information,
25
26 34 particularly in low literacy settings
27
28
29
30
31
32
33
34
35
36
37

38 INTRODUCTION

39 Type 2 diabetes mellitus (hereto referred to as diabetes) is amongst the foremost health
40 challenges facing policy makers in Thailand. Its prevalence has more than tripled over the last
41 two decades to an estimated 4 million adults (age adjusted prevalence 7.1%) living with diabetes
42 in 2015.^{1,2} Diabetes is associated with several macrovascular (e.g. ischaemic heart disease) and
43 microvascular complications (e.g. nephropathy, retinopathy, neuropathy, and foot disease),
44 which primarily account for the considerable death and disability (of which diabetes is the 5th
45 leading cause in Thailand). In addition, diabetes in Thailand causes two-fold increase in
46 healthcare expenditure and significant loss of economic productivity—of both people with
47 diabetes and their carers.¹⁻⁴

48 The complications of diabetes can be largely prevented or delayed through lifestyle change and
49 medication when necessary, and regular screening for early detection and management of
50 complications to control risk factors such as blood glucose, lipids and blood pressure.^{3,4} Under
51 Thailand's universal health coverage, nearly everyone diagnosed with diabetes receives timely
52 medical care (>97%) and has access to screening. Yet, surveys suggest that only about half of the
53 people with diabetes achieve optimal control of risk factors or receive annual screening for
54 microvascular complications (53-60%).^{1,5} Limited data support a lack of engagement and self-
55 management skills among those diagnosed with diabetes as the main underlying reasons for this.⁶
56 Successful management of diabetes involves a considerable degree of self-management. People
57 with diabetes need to adhere to multiple behaviours, including healthy lifestyles, regular
58 monitoring and medication, problem-solving and healthy coping strategies. In this, they are
59 greatly supported by diabetes self-management education (DSME), defined as 'a collaborative
60 and ongoing process intended to facilitate the development of knowledge, skills, and abilities
61 that are required for successful self-management of diabetes'.⁷ Evidence from over 100 studies,

1
2
3 62 including many randomised controlled trials conducted predominantly in high-income countries,
4
5 63 suggests that DSME programmes are associated with improvements in a range of behavioural
6
7 64 outcomes (knowledge, behaviours, self-efficacy, psychosocial), and clinical outcomes
8
9
10 65 (physiological risk factors, screening for complications, quality of life),^{8,9} and are cost-
11
12 66 effective.¹⁰ Therefore, DSME programmes are recommended by most clinical guidelines.⁷
13
14
15 67 However, there is considerable heterogeneity in the effectiveness of DSME programmes^{8,9}.
16
17 68 Programmes that are more effective usually offer more than 10 hours of contact between trainers
18
19 69 and patients, incorporate behavioural approaches and provide longer-term support mechanisms.
20
21 70 However, providing intensive and sustained support has cost implications, resulting in ongoing
22
23 71 efforts to identify more cost-efficient ways to deliver DSME, notably through use of lay health
24
25 72 workers or peer educators, such as Thai village health volunteers (VHV).
26
27
28 73 Peers can support sustained changes in complex health behaviours by providing assistance in
29
30 74 daily management, social and emotional support, linkage to clinical care, and ongoing
31
32 75 availability of support.^{11,12} Unlike the educational/psychological framework of professional
33
34 76 support, peer support operates on a social support framework. Although traditionally restricted to
35
36 77 those with experience of disease, the definition of peers has been expanded to include other non-
37
38 78 professionals with a close relationship with the community (e.g. VHV).¹³ However, despite
39
40 79 widespread interest, empirical data on effectiveness of peers in supporting behaviour change in
41
42 80 chronic diseases, including diabetes, is limited and inconsistent.^{14,15} In an earlier review, the
43
44 81 World Health Organisation did not find sufficient evidence to recommend peer support
45
46 82 programmes as a policy option for diabetes management in LMICs.¹⁶ Whereas many studies on
47
48 83 the effectiveness of DSME programmes come from high-income countries (HIC), there is a
49
50 84 dearth of data from LMIC settings on cost-effectiveness, acceptability and potential adverse
51
52
53
54
55
56
57
58
59
60

1
2
3 85 consequences of peer support programmes, as well as optimal strategies for mobilising and
4
5 86 integrating peers in diabetes care pathways.^{12,17-18}
6

7
8 87 In the Thai healthcare system, structured DSME is not routinely available. While several small-
9
10 88 scale studies from Thailand have demonstrated that DSME can strengthen self-management of
11
12 89 diabetes, negative perceptions of educational programmes and concerns about the burden on
13
14 90 existing staff time and costs, have so far prevented the introduction of DSME.^{1,18} However,
15
16 91 recent policy developments in Thailand are supportive of DSME introduction, if a scalable
17
18 92 model can be found. We therefore hypothesise that a nurse-led and/or peer-assisted model for
19
20 93 DSME delivery will be effective in improving blood glucose among people with diabetes, with
21
22 94 the peer-assisted model being the more scalable option for the Thai healthcare system. We
23
24 95 propose to evaluate this through a three-arm cluster randomised controlled trial.
25
26
27
28
29
30

31 97 **METHODS AND ANALYSIS**

32 33 98 **Study design**

34
35 99 This study is a MRC complex intervention,¹⁹ three-arm cluster randomised controlled trial.
36
37 100 Primary care units from within two provinces: Chiang Mai and Lampang will be randomised for
38
39 101 patients to receive either the nurse-led or peer-assisted DSME intervention or standard care (brief
40
41 102 education session by a nurse). Assessments will be undertaken at baseline, 6- and 12-month
42
43 103 follow up. A process and cost-effective evaluation will also be conducted.
44
45
46
47
48

49 105 **Setting and Participant Selection**

50
51 106 Potential participants requiring a DSME intervention will be recruited from 21 primary care units
52
53 107 in Chiang Mai (7 primary care units) and Lampang provinces (14 primary care units) in northern
54
55
56
57
58
59
60

1
2
3 108 Thailand. Chiang Mai is a province of over 1.4 million people with 24 district hospitals and
4
5 109 about 250 primary care units. Lampang is a province of approximately 700,000 people with 12
6
7
8 110 district hospitals and about 140 primary care units. While diabetes is diagnosed at tertiary and
9
10 111 district hospitals, it is managed at the primary care unit health centres, which are served by a full-
11
12 112 time nurse (doctor visits weekly), and 10-15 village health volunteers (VHV) linking patients in
13
14 113 the community.

15
16
17 114 From clinical records, we will recruit all new referrals for diabetes management and patients
18
19 115 with uncontrolled diabetes diagnosed in the past 3 years at the 21 primary care units over a 9-
20
21 116 month period (N=693). Posters and information sheets will be used to provide necessary, trial-
22
23 117 related information to prospective participants (Figure 1).
24
25

26 118

27
28 119 Participants presenting to one of the 21 primary care units will be included if they are:

- 29
30
31 120 1. Over 18 years of age with a new referral for type 2 diabetes management;
32
33 121 2. Over 18 years of age with uncontrolled diabetes ($HbA1c > 7\%$) within the first three
34
35 122 years of diagnosis;
36
37 123 2. Willing and able to attend educational group meetings; and
38
39 124 3. Available for 6- and 12-month follow-up visits
40
41

42 125 Participants will be excluded if they:

- 43
44 126 1. Have advanced diabetic complications such as diabetic nephropathy, diabetic
45
46 127 retinopathy, or amputations; or if they are pregnant;
47
48 128 2. Have learning disabilities, dementia or active severe mental illness; or
49
50 129 3. Lack the capacity to give voluntary, informed consent.
51
52
53

54 130
55
56
57
58
59
60

131 **Randomisation**

132 Stratified by province, 21 primary care units (7 from Chiang Mai and 14 from Lampang) will be
133 randomised to provide one of three interventions: (1) nurse-led DSME; (2) nurse-led DSME with
134 peer assistance (provided by Thai village health volunteers, VHV); or (3) standard care (brief
135 education session by a nurse), resulting in seven primary care units in each arm of the study. All
136 primary care units follow protocols for diabetes management as outlined by national guidelines.
137 Randomisation by province will minimise any variation in practice between the different primary
138 care units.

139

140 **Sample size calculation**

141 The trial is powered to detect a difference in HbA1c of 0.6% (SD 1.5%) between control and
142 intervention arms, based on the effect size of 0.6% noted in a previous diabetes management
143 study in Thailand²⁰, and the fact that an increase in HbA1c of ~0.5% was associated with
144 increased mortality among people with diabetes²¹. An ICC between hospitals of 0.02 was
145 assumed based on a similar study which found that The intraclass correlation for HbA1c at three
146 years was 0.02 (95% confidence interval 0.00 to 0.08)²². Allowing for a loss to follow up rate of
147 20%, 693 participants are needed from 21 primary care units (7 in each trial arm arm) to achieve
148 80% power at 2.5% significance level.

149

150 **Informed consent**

151 Written informed consent will be obtained from all study participants in Thai before any study
152 procedures are undertaken including enrolment, intervention allocation, follow-up interviews and
153 blood draws. Local research assistants will explain the study to patients using the patient

1
2
3 154 information sheet (supplementary file). The right of the patient to refuse to participate without
4
5 155 giving reasons will be respected.
6
7
8 156

9
10 157 **Intervention description and delivery**

11
12 158 The DSME programme has been developed using a structured process. This included a desk and
13
14 159 literature review and focus groups with local nurses and VHV to develop a paper prototype of
15
16 160 the intervention, including a hypothesised pathway of action (e.g. common-sense model of
17
18 161 illness, empowerment, discovery learning, social learning, and social support) and a training
19
20 162 manual for nurses and VHV. In addition, seven brief films (5-6 minutes long) have been
21
22 163 developed and have been used to trigger discussions on key topic areas during DSME
23
24 164 intervention meetings covering such topics as medical adherence, dietary recommendation,
25
26 165 physical activity and stress management. Films will be used in the intervention as they are
27
28 166 increasingly recognised as a highly effective medium for improved recall when communicating
29
30 167 large amounts of information, particularly in low literacy settings.²³ Films will be in the local
31
32 168 language and use local people.
33
34
35
36
37
38
39

40 170 Our DSME programme will consist of 4 modules. Module 1 covers the general overview of
41
42 171 diabetes, treatment targets and goal settings. Module 2 covers diet and nutrition. Module 3
43
44 172 covers physical activity and exercise while module 4 covers stress management and mental
45
46 173 health. Each module takes approximately 1.5 hours. Each participant is given an information and
47
48 174 self-assessment booklet which covers all contents and materials for the four modules.
49
50
51

52
53 175 In addition to routine care, in the nurse-led arm, the nurse will deliver the DSME to groups of 5-
54
55 176 10 participants per session within the first months after enrolment. The participants in the nurse-
56
57
58
59

1
2
3 177 led arm will also be given a refresher session going over all 4 modules again at 6 months after
4
5 178 enrolment. For the peer-assisted arm, a peer volunteer will participate as an assistant to the nurse
6
7 179 in the first DSME session. However, the peer will lead the refresher course at 6 months. In
8
9
10 180 addition, participants in the peer-led arm will received monthly contact with the peer either via a
11
12 181 home visit or telephone call. During these brief 15-20 minute monthly contacts, peers will ask
13
14 182 about the progress made, providing encouragement if plans for self-management are being
15
16 183 followed or discussing ways to overcome barriers and set new goals if obstacles are identified.
17
18
19 184 (Table 1)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

185 Table 1 Summary DSME Delivery

Month	Routine care	Nurse-led DSME	Peer-assisted DSME**
0	Individual session	Nurse provides DSME (4 modules)	Nurse provides DSME (4 modules) with peer volunteers to assist the sessions
6	Individual session	Refresher course (4 modules) provided by nurse	Refresher course (4 modules) led by peers
12	Outcome assessment	Outcome assessment	Outcome assessment

186 * participants in the peer-led arm will received monthly contact with the peer either via a home
187 visit or telephone call.

188
189 The intervention will be piloted at four community hospitals with four nurses and four VHV who
190 will be trained to deliver the DSME programme to groups of 5-10 persons with diabetes. This
191 will allow for refining the intervention, ensuring data collection can be completed as specified,
192 and to check our assumptions and processes for the trial. For the main trial, a two-day workshop
193 will be held such that at least one nurse and one VHV from each primary care unit will be trained
194 by the Thai research team to deliver the DSME programme at the community hospital or
195 neighbourhoods as appropriate. The trial coordinator will conduct periodic site visits as
196 additional training as requested and a line of communication will be established between the
197 research team and each site to answer any issues which may arise.

198

1
2
3 199 A process evaluation using qualitative methods will be conducted during the trial period and at
4
5 200 the end of the study. Observations including video recordings of intervention delivery will be
6
7 201 made. We plan to conduct 5-10 focus group among providers (nurses and village health
8
9 202 volunteers) to explore healthcare professionals' perspectives regarding their experience and
10
11 203 implementation of the DSME programme, including views on the cultural transferability of
12
13 204 DSME and scalability to the Thai context. In addition, we planned to conduct 20 structured
14
15 205 interviews with patients. These evaluations will help assess intervention delivery (fidelity, dose
16
17 206 and reach), clarify causal mechanisms (those hypothesised by theory of change developed within
18
19 207 the project or emergent mechanisms identified), and detail contextual factors (barriers,
20
21 208 facilitators) associated with variation in outcomes.²⁴ The process evaluation will also consist of
22
23 209 one-to-one interviews with clinicians and policy makers and direct observations of patients. Data
24
25 210 for economic evaluations (resource usage and quality of life using EQ-5D²⁵) will be obtained
26
27 211 prospectively alongside the trial.
28
29
30
31
32

33 212

35 213 **Standard care**

36
37 214 Patients in the control group will receive standard care in the form of a brief didactic educational
38
39 215 session at the time of diagnosis of diabetes.²⁶
40
41
42

43 216

45 217 **Study outcomes**

46
47 218 The two primary outcomes of the intervention are a difference in trial arms at one-year follow-up
48
49 219 in HbA1c and cardiovascular risk score. There is a growing recognition of the importance of
50
51 220 combining tight glycaemic control with reduction in other cardiovascular risk factors for
52
53 221 prevention of or reduction in complications.⁴ The cardiovascular risk will be estimated by the
54
55
56
57
58
59

222 Thai cardiovascular risk score model, which estimates the risk of dying from any cardiovascular
 223 disease over 10 years based on age, gender, smoking habits, total cholesterol and systolic blood
 224 pressure, as it has been calibrated for use in a Thai population.²⁷

225 Additional secondary outcomes include changes at one year for biophysical data, psychosocial
 226 and lifestyle data and intervention related data, as described in Table 2.

227

228 **Table 2:** Primary and secondary Outcome measures

Primary outcomes	Measures or questionnaires
Haemoglobin A1c levels (HbA1c)	HbA1c will measure the average blood glucose (sugar) levels over the past two to three months
Thai Cardiovascular risk score	Estimates the risk of dying from any cardiovascular disease over 10 years based on age, gender, smoking habits, total cholesterol and systolic blood pressure.
Secondary outcomes	Measures or questionnaires
Biological and physical measures	Body weight, Body Mass Index; BMI, Blood lipids (LDL-C), waist circumference
Quality of life	WHOQOL BREF- A 26 item questionnaire developed by WHO to assess quality of life in adults ²⁸
	The European Quality of Life questionnaire; EuroQol EQ-5D 5L ²⁵ EQ-5D is a quality of life measure that includes five quality of life questions on mobility, self-care, usual activity, pain, anxiety/depression and a scale of 0 to 100 on how the person is feeling on that day.

<p>Depression</p>	<p>Hospital Anxiety and Depression Scale; HADS²⁹</p> <p>HADS measures depression and anxiety that will address psychological change with a scale from 0 to 3.</p>
<p>Stress</p>	<p>Perceived stress questionnaire; PSS³⁰</p> <p>PSS is a psychological instrument for measuring the perception of stress. Ten items with a scale from 1 to 4.</p>
<p>Physical activity</p>	<p>International Physical Activity Questionnaire; IPAQ³¹</p> <p>Short form IPAQ is an assessment of physical activity comprising of seven questions. There are two forms of output from scoring the IPAQ. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). MET minutes represent the amount of energy expended carrying out physical activity.</p>
<p>Diabetes knowledge and skills</p>	<p>Brief diabetes illness perception questionnaire; B-IPQ³².</p> <p>B-IPQ has nine components of which the first five questions assess the cognitive representation of illness perception, two of the questions assess the emotional representation, one item assesses comprehensibility and one item on the root cause of the illness</p> <hr/> <p>Diabetes Self-Management Education and Support; DMSES³³.</p> <p>DMSES is one of the most widely used scale in measuring self-efficacy in type 2 diabetes management. The Thai-DMSES has twenty questions which has been demonstrated to have good psychometric properties³⁴</p>

	<p>Summary of Diabetes self-care activities questionnaire SDSCA³⁵</p> <p>SDSCA is a diabetes self-care activities questionnaire focusing on general diet, diabetes-specific diet, physical activity, blood-glucose testing, foot care, and smoking.</p>
Satisfaction with intervention	<p>Chronic Illness Resources survey (CIRS)³⁶</p> <p>CIRS is a questionnaire to represent patient's received support. Individual's support for behavioural-specific disease management is assessed: proximal support e.g. friend and family and distal factor e.g. neighbourhood or community.</p>
	<p>Modified Medical Interview Satisfaction scale (MISS-21)³⁷</p> <p>MISS-21 is a questionnaire to measure patient satisfaction with patient and health care professional communication/consultation.</p>

229

230 **Data collection and follow-up**

231 Each participant will be involved in the study for 12 months after taking consent and baseline
 232 data. The trial is expected to start January 2020 and finish October 2021.

233

234 Data collection methods will include:

235 a) Questionnaires: Questionnaire data will be collected face-to-face by research assistants for the
 236 full sample at baseline, 6 and 12 months at the community hospital where participants are
 237 recruited (Table 1). A custom-designed form linked to RedCap will be used to collect, validate,
 238 verify, and store respondents' data where possible or else data will be collected via paper forms
 239 and double-entered into the databases. All data files and databases will be password protected.

240

1
2
3 241 b) Biological samples: Blood samples will be collected at baseline, 6 and 12 months, to measure
4
5 242 fasting blood glucose, HbA1c and lipids, coordinating where possible with the annual routine
6
7 243 tests offered to patients to reduce duplication. All blood samples will be administered from
8
9
10 244 participants by trained phlebotomists. Data will be linked to the participant information using a
11
12 245 unique respondent ID, which will be assigned to all study participants.
13
14

15 246
16
17 247 c) Interviews: During the delivery of the intervention, a process evaluation using a subset of
18
19 248 participants will be followed up using in-depth interviews and focus group discussions. These
20
21 249 will be audio-recorded. Data will be collected using a range of qualitative methods: a) one-to-one
22
23 250 interviews, and focus group discussions with nurses, health volunteers, people with diabetes and
24
25 251 their carers (5-10 focus groups, and 20 semi-structured interviews) and b) ethnography through
26
27 252 direct observations including video recordings of intervention delivery, and unstructured
28
29 253 interviews with clinical managers and policy makers. The data collected will be used to capture
30
31 254 the range of experiences of the intervention, and identify unanticipated pathways to generate new
32
33 255 theories as well as exploring the scalability of the intervention.
34
35
36
37

38 256

39 257 **Trial follow-up appointments**

40
41
42 258 The research team will hold weekly briefings with the study coordinators to generate a list of
43
44 259 priority areas and loss to follow-up participant lists. Arrangements to follow-up participants who
45
46 260 have not turned up for their appointment will be made, with attempts to contact participants
47
48 261 through SMS, phone calls, or house visits. Participants will be declared loss to follow-up if they
49
50 262 do not show for a month and are untraceable.
51
52
53

54 263
55
56
57
58
59
60

264 **Data management**

265 A data collection protocol will be developed, and the study coordinator in Thailand will provide
266 training to fieldworkers before data collection commences. Validation will be performed a
267 random sample of questionnaire data by crosschecking with clinic records. Any discrepancies
268 will be followed-up and addressed by field workers, re-contacting participants to clarify as
269 necessary. Using Redcap (<https://redcap.med.cmu.ac.th>), quantitative data will be entered
270 directly via a form with built-in data checks to minimise transcription errors (or where necessary
271 collected on paper and later double entered into the electronic form). Post entry checks will be
272 conducted by exploring the distribution, ranges, and outliers of each variable. All hospital
273 laboratories have their own internal quality assurance protocols and are also linked to a national
274 external quality assurance mechanism. Fieldworkers will be trained in qualitative methods and
275 an interview schedule will be devised.

277 **Statistical analysis**

278 1. Quantitative analysis

279 Available outcome data will be analysed on an intention-to-treat basis. Potential clustering of
280 outcomes (HbA1c at 12 months and CVD risk score at 12 months) at the level of community
281 primary care units will be accounted for using random intercept models. and adjusted for
282 baseline values. To improve precisions of the estimates, outcomes will be adjusted for their
283 baseline values. In case of baseline imbalances of relevant covariates (e.g. age, education level,
284 body mass index), judged by statistical significance at $p < 0.05$, we will conduct a secondary
285 analysis adjusting for these covariates.

287 2. Qualitative analysis

288 Qualitative data from interviews, focus groups and direct observations be will transcribed and
289 analysed using NVivo software. The data will be analysed using a descriptive, phenomenological
290 approach to understand participants' experiences and interpret them within their respective
291 cultural contexts. Comparative analysis will compare and contrast these themes across
292 participants. Deviant cases will be actively sought throughout the analysis and emerging ideas
293 and themes modified in response. In addition, thematic analysis will be used to inform elements
294 of scalability and to produce a set of considerations in making decisions about the scalability of
295 the intervention.

297 3. Cost-effective analysis

298 Data for economic evaluation (resource usage and quality of life using EQ-5D) will be obtained
299 prospectively alongside the trial. We will aim to capture all health service contacts, as well as
300 out-of-pocket expenses and medication use. Educator training costs will be included, as well as
301 minimal intervention material costs (as most will be made available freely after the trial). Utility
302 values from EQ-5D will be derived using a Thai tariff. Incremental cost utility will be estimated
303 from the Thai health system and societal perspectives, to provide incremental cost-effectiveness
304 ratio and probability of being cost-effective at Thai government's willingness to pay threshold of
305 160,000 baht/QALY.

310 **ETHICS AND DISSEMINATION**

311 This study is to be conducted according to the international standards of Good Clinical Practice
312 (International Conference on Harmonization guidelines), Declaration of Helsinki, and
313 International Ethical Guidelines for Biomedical Research Involving Human Subjects, applicable
314 national government regulations, and institutional research policies and procedures. All
315 investigators received GCP training at the onset of the study. Ethical approval was obtained prior
316 to commencement of the project from Chiang Mai University [No 326/2018] and the London
317 School of Hygiene & Tropical Medicine [16113/RR/12850]. The study protocol, informed
318 consent form, participant's information sheet and other relevant information has been approved.
319 Any future amendments of the protocol shall be submitted to and approved by the Institutional
320 Review Board (IRB) before implementation

321

322 **Trial monitoring and oversight**

323 The role of the Trial Steering Committee (TSC) is to provide overall supervision of the trial. The
324 TSC will meet every six months. The TSC will include experts in the field of DSME, health
325 psychology and clinical trials, as well as an independent Chair. In addition, we will have patient
326 and carer representatives and policy representation.

327

328 **Dissemination**

329 Expected output and impact research findings will be disseminated to scientific audiences at
330 major conferences and published in high-impact, open-access scientific journals; planned
331 publications include those on intervention development, primary trial results, and process
332 evaluation, and health systems analysis, at a minimum. This study is expected to have a major

1
2
3 333 policy impact due to the close involvement of a key policy maker in the project. Towards the end
4
5 334 of the study a dedicated workshop will be held with key governmental stakeholders to
6
7 335 disseminate the recommended model for DSME implementation in Thailand and encourage
8
9 336 inclusion of a large-scale scientific evaluation into any national implementation of the scheme.
10
11
12
13

337

14 338 **Contributors:** CA, SS, OQ, PM, SK were involved in conception and trial design. CA, KP, PM
15
16 339 and SK wrote the first draft of the trial design proposal. KR, WT, KH, KK were involved in
17
18 340 critical revision of the trial design proposal. All authors contributed to finalising the trial
19
20 341 protocol. CA, KP, IPN, CP, AH, NW were involved with preparation of the manuscript for
21
22 342 submission. All authors reviewed the manuscript and approved the manuscript for publication.
23
24
25

343

26 344 **Funding**

27
28 345 This study is supported by UK Medical Research Council (MRC) grant number
29
30 346 [MR/R020876/1] and the Thailand Research Fund (TRF) grant number [DBG6180007].
31
32
33
34

347

35 348 **Data availability**

36
37 349 Data will be shared upon reasonable request
38
39

350

40 351 **Patient and Public Involvement**

41
42 352 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or
43
44 353 dissemination plans of our research
45
46
47
48

354

355

1
2
3 356 **Trial registration and version**
4

5 357 The trial has been registered (ClinicalTrials.gov ID NCT03938233 Version 3 last update January
6
7
8 358 18,2020)
9

10 359 **Trial sponsor**
11

12 360 This study is sponsored by London School of Hygiene & Tropical Medicine, Keppel Street,
13
14 361 London WC1E 7HT, UK [16113].
15
16

17 362 **Competing interests**
18

19 363 None declared
20

21 364 **Ethics approval**
22

23
24 365 The study has been approved by the Chiang Mai University Research Ethics Committee
25
26 366 [326/2018] and the London School of Hygiene & Tropical Medicine [16113/RR/12850].
27
28

29 367
30

31 368 **Figure 1 Legend: Trial flow diagram**
32

33 369 **REFERENCES**
34

- 35 370 1. Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature
36
37 review of the burden, costs, and outcomes. *Glob Health* 2013; 9: 11.
38 371
39
40 372 2. International Diabetes Federation. *IDF Diabetes Atlas Seventh Edition*. 2015.
41
42 373 3. Effect of intensive blood-glucose control with metformin on complications in
43
44 overweight patients with type 2 diabetes (UKPDS 34). *The Lancet* 1998; 352: 854–
45 374 65.
46
47 375
48
49 376 4. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial
50
51 377 intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J*
52
53 *Med* 2003; 348: 383–93.
54 378
55
56
57
58
59
60

- 1
2
3 379 5. Rangsin R. An assessment of quality of care among patients diagnosed with type 2
4
5 380 diabetes and hypertension visiting hospitals of ministry of public health and Bangkok
6
7 381 Metropolitan Administration in Thailand. 2012.
- 8
9
10 382 6. Auemaneekul N, Chandanasotthi P, Rawiworrakul T, et al. Community partnership,
11
12 383 context-based intervention and diabetes control in Thailand. *J Public Health* 2016;
13
14 384 46: 236–47.
- 15
16
17 385 7. Haas L, Maryniuk M, Beck J, et al. National standards for diabetes self-management
18
19 386 education and support. *Diabetes Educ* 2012; 38: 619–629.
- 20
21
22 387 8. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults
23
24 388 with type 2 diabetes mellitus: A systematic review of the effect on glycemic control.
25
26 389 *Patient Educ Couns* 2016; 99: 926–43.
- 27
28
29 390 9. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programmes for type 2 diabetes
30
31 391 mellitus: A systematic review and network meta-analysis. *Ann Intern Med* 2015;
32
33 392 163: 848.
- 34
35
36 393 10. Doyle G, O'Donnell S, Quigley E, et al. Patient level cost of diabetes self-
37
38 394 management education programmes: an international evaluation. *BMJ Open* 2017; 7:
39
40 395 e013805.
- 41
42
43 396 11. Fisher EB, Boothroyd RI, Elstad EA, et al. Peer support of complex health behaviors
44
45 397 in prevention and disease management with special reference to diabetes: Systematic
46
47 398 reviews. *Clin Diabetes Endocrinol* 2017; 3. DOI:10.1186/s40842-017-0042-3.
- 48
49 399 12. Dale JR, Williams SM, Bowyer V. What is the effect of peer support on diabetes
50
51 400 outcomes in adults? A systematic review. *Diabet Med* 2012; 29: 1361–77.
52
53
54 401

- 1
2
3 402 13. Norris SL, Chowdhury FM, Van Le K, et al. Effectiveness of community health
4
5 403 workers in the care of persons with diabetes. *Diabet Med J Br Diabet Assoc* 2006;
6
7 404 23: 544–56.
8
9
10 405 14. World Health Organization. Peer support programmes in diabetes: report of a WHO
11
12 406 consultation 5-7 November 2007. Geneva, Switzerland: WHO, 2008.
13
14
15 407 15. Fisher EB, Boothroyd RI, Coufal MM, et al. Peer support for self-management of
16
17 408 diabetes improved outcomes in international settings. *Health Aff (Millwood)* 2012;
18
19 409 31: 130–9.
20
21
22 410 16. Trento M, Gamba S, Gentile L, et al. Rethink Organization to iMprove Education
23
24 411 and Outcomes (ROME0): A multicenter randomized trial of lifestyle intervention by
25
26 412 group care to manage type 2 diabetes. *Diabetes Care* 2010; 33: 745–7.
27
28
29 413 17. Werfalli M, Raubenheimer P, Engel M, et al. Effectiveness of community-based
30
31 414 peer-led diabetes self-management programme (COMP-DSMP) for improving
32
33 415 clinical outcomes and quality of life of adults with diabetes in primary care settings
34
35 416 in low and middle-income countries (LMIC): A systematic review and meta-analysis.
36
37 417 *BMJ Open* 2015; 5: e007635.
38
39
40 418 18. Keeratiyutawong P, Hanucharunkl S, Melkus G, Vorapongsathon OPT.
41
42 419 Effectiveness of a self-management programme for Thais with type 2 diabetes. *Thai*
43
44 420 *J Nurs Res* 2006; 10: 85–97.
45
46
47 421 19. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
48
49 422 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*
50
51 423 2008; a1655.
52
53
54
55
56
57
58
59

- 1
2
3 424 20. Wattana C, Srisuphan W, Pothiban L, Upchurch SL. Effects of a diabetes self-
4
5 425 management programme on glycaemic control, coronary heart disease risk, and
6
7 426 quality of life among Thai patients with type 2 diabetes. *Nurs Health Sci* 2007; 9:
8
9 427 135–41.
- 10
11
12 428 21. Wan EYF, Fung CSC, Wong CKH, Chin WY, Lam CLK. Association of
13
14 429 hemoglobin A1c levels with cardiovascular disease and mortality in Chinese patients
15
16 430 with diabetes
- 17
18
19 431 22. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self-
20
21 432 management programme (DESMOND) for people with newly diagnosed type 2
22
23 433 diabetes mellitus: Three-year follow-up of a cluster randomised controlled trial in
24
25 434 primary care. *BMJ* 2012; 344: e2333–e2333.
- 26
27
28 435 23. Tuong W, Larsen ER, Armstrong AW. Videos to influence: A systematic review of
29
30 436 effectiveness of video-based education in modifying health behaviors. *J Behav Med*
31
32 437 2014; 37: 218–33.
- 33
34
35 438 24. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions:
36
37 439 Medical Research Council guidance. *BMJ* 2015; 350: h1258–h1258.
- 38
39
40 440 25. Kimman M, et al. Validity of the Thai EQ-5D in an occupational population in
41
42 441 Thailand. *Qual Life Res* 2013 Aug; 22(6):1499-506.
- 43
44
45 442 26. Clinical Practice Guidelines for Diabetes. Diabetes Association of Thailand, 2017.
46
47 443 ([https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-](https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-guideline-diabetes-care-2017)
48
49 444 [guideline-diabetes-care-2017](https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-guideline-diabetes-care-2017))
- 50
51 445 27. Aekplakorn A, Bunnag P, Woodward M. et al. Risk score for predicting incident
52
53 446 diabetes in the Thai population. *Diabetes Care* 2006 Aug; 29(8):1872-1877

- 1
2
3 447 28. Mahatnirunkul S, Tuntipivanaskul W, Pumpisanchai W, et al. Comparison of the
4
5 448 WHOQOL-100 and the WHOQOL-BREF. *Journal of Mental Health of Thailand*
6
7 449 1998; 5: 4-15.
8
9
10 450 29. Nilchaikovit T. et al. Development of Thai version of hospital anxiety and depression
11
12 451 scale in cancer patients. *J Psychiatr Assoc Thailand* 1996; 41(1):18-30.
13
14 452 30. Wongpakaran N, Wongpakaran T. The Thai version of the PSS-10: An investigation
15
16 453 of its psychometric properties. *BioPsychoSocial Medicine* 2010: 4:6
17
18 454 31. Rattanawiwatpong P, et al. Validity and reliability of the Thai version of Short
19
20 455 Format International Physical Activity Questionnaire (IPAQ). *J Thai Rehabil* 2006;
21
22 456 16(3):147-160.
23
24 457 32. Leelacharas S, et al. Illness perceptions, lifestyle behaviours, social support and
25
26 458 cardiovascular risks in people with Hypertension in Urban and Rural Areas of
27
28 459 Thailand. *Pacific Rim Int J Nur Res* 2015; 19
29
30 460 33. Lamsumang, W. The development of the Thai version of the diabetes management
31
32 461 self-efficacy scale (T-DMSES) for older adults with type 2 diabetes. State University
33
34 462 of New York at Buffalo, New York; 2009.
35
36 463 34. Sangruangake M, Jirapornkul C, Hurst C. Psychometric properties of diabetes
37
38 464 management self-efficacy in Thai type 2 diabetes mellitus patients: A multicenter
39
40 465 study. *Int J Endocrinol*. 2017;2017:2503156. doi:10.1155/2017/2503156)
41
42 466 35. Keeratiyatawong, P, Hanucharumkul, S., Melkus, G. D. E., Panpakdee, O.,
43
44 467 Vorapongsathorn T. Effectiveness of a self-management programme for Thais with
45
46 468 type 2 diabetes. *Thai J Nurse Res*. 2006; 10: 85-97
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 469 36. Manit A, et al. Development of needs and resources for self-management assessment
4
5 470 instrument in Thais with type 2 diabetes: Cross-cultural adaptation. *J Med Assoc*
6
7 471 *Thai* 2011; Vol. 94 No. 11.
8
9
10 472 37. Meakin R and Weinman J. The 'Medical Interview Satisfaction Scale' (MISS-21)
11
12 473 adapted for British general practice. *Family Practice* 2002; 19:257–263.
13
14
15 474

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Trial flow diagram
27x20mm (1200 x 1200 DPI)



Participant Information Sheet

Title of Project: Delivering Diabetes Self-Management Education in Thailand

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

The London School of Hygiene and Tropical Medicine (LSHTM) are conducting research for people with type 2 diabetes in Chiang Mai Thailand who have recently been diagnosed. The purpose of this study is to provide diabetes self-management education (DSME) by trained nurses and peer health care volunteers for those recently diagnosed.

This is a 3 arm cluster randomised trial where your service provider has been randomised to one of the following 3 interventions: 1) usual treatment 2) Nurse led DSME 3) Peer led DSME.

Why have I been asked to take part?

You have been invited because your healthcare provider is involved in the study and has identified you as being newly diagnosed with type 2 diabetes.

Do I have to take part?

No. It is up to you to decide to take part or not. If you don't want to take part, that's ok. Your doctor will still care for you and your decision will not affect the quality of care you receive.

We will discuss the study together and give you a copy of this information sheet. If you agree to take part, we will then ask you to sign a consent form.

What will happen to me if I take part?

Enrolling you in the study

If you are interested in taking part the research assistant will go through the information sheet with you. If you are happy with the information provided you may complete the consent form.

At this point you will also have the opportunity to raise with the researcher any questions you might have about the study. You do not have to enter the study unless you feel completely happy with what you are being asked to do.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 1 of 5



Participating in a diabetes education programme

You will be invited to attend a diabetes self-management educational programme. This programme will consist of a number of sessions delivered as monthly meetings led by community health volunteers or nurses. Short films about living with diabetes will be shown to introduce key topics.

The education and skills training will be followed by an open discussion session to discuss common challenges and solutions, set lifestyle goals and seek advice.

Collecting information

If you are happy to proceed with the study the researcher will then ask a series of questions relating to your health. This will be through completing a questionnaire booklet. These baseline questions will take about twenty minutes to complete. We will also take blood samples as the beginning of the study from trained phlebotomists.

Each participant will be compensated 200 baht for each of the baseline, 6 month and 12 month visit.

Follow up

Six months and twelve months after you have entered the study we will contact you again to ask you a further set of questions and blood samples to see how you are feeling now.

How is taking part in the study different from usual care?

Additional support and education may be provided through the study through the self-management education programme.

Whilst you are taking part in the study you will continue to be looked after by your healthcare providers, as normal. No treatment will be withheld from you during the course of this study.

The researcher will want you to complete some questionnaires at the beginning of the study and after six and twelve months. You may be asked to take part in an interview with a researcher.

What are the possible risks and disadvantages?

It will take some time to complete the questionnaire, around twenty minutes to complete. If you agree to be further interviewed, then this will also mean time will be needed to attend the interview. You may find minor discomfort from the taking blood samples. We will have trained phlebotomists to take the blood sample.

What are the possible benefits?

We cannot promise the study will help you but the information we get from the study will help our knowledge and understanding of this research area within diabetes self-management education in Thailand.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 2 of 5



What if something goes wrong?

If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions <+66(0)616852307>. If you remain unhappy and wish to complain formally, you can do this by contacting <if LSHTM is the sponsor: Patricia Henley at rgio@lshtm.ac.uk or +44 (0) 20 7927 2626>

The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you may be eligible to claim compensation.

Can I change my mind about taking part?

Yes. You can withdraw from the study at any time. You just need to tell your doctor that you don't want to be in the study anymore. Your doctor will still care for you.

If you withdraw from the study we will destroy all your identifiable samples/ tape recorded interviews, but we will need to use the data collected on you up to your withdrawal

Or

You can withdraw from treatment but keep in contact with us to let us know your progress. Information collected may still be used. Any stored blood or tissue samples that can still be identified as yours will be destroyed if you wish, or will continue to be stored for further research.

What will happen to information collected about me?

All information collected about you will be kept private. Only the study staff and authorities who check that the study is being carried out properly will be allowed to look at information about you. Data may be sent to other study staff in London or in Chiang Mai but this will be anonymised. This means that any information about you which leaves the hospital, will have your name and address removed so that you cannot be recognised.

Your doctor will send some details about you to the study team in Chiang Mai University who will store it securely. Your personal details will be kept in a different safe place to the other study information and will be destroyed within 10 years of the end of the study.

At the end of the project, the study data will be archived at Chiang Mai University. The data will be made available to other researchers worldwide for research and to improve medical knowledge and patient care. Your personal information will not be included and there is no way that you can be identified.

What will happen to the results of this study?

The study results will be published in a medical journal so that other doctors can learn from them. Your personal information will not be included in the study report and there is no way that you can be identified from it.

Who is organising and funding this study?

London School of Hygiene & Tropical Medicine is the sponsor for the research and they have full responsibility for the project including the collection, storage and analysis of your data.

This study is funded by the Medical Research Council UK and The Thailand Research Fund

Who has checked this study?

All research involving human participants is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by The London

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 3 of 5



School of Hygiene and Tropical Medicine Research Ethics Committee (<ref: 16113>). The Research Ethics Committee, Faculty of Medicine, Chiang Mai University (No 326/2018) has also reviewed the study and have agreed that it is okay for us to ask people to take part.

Further information and contact details

Thank you for taking time to read this information leaflet. If you think you will take part in the study please read and sign the consent form.

If you would like any further information, please contact Dr. Chaisiri Angkurawaranon, MD, who can answer any questions you may have about the study.

Contact details: Chaisiri Angkurawaranon, Department of Family Medicine, Faculty of Medicine, Chiang Mai University. Tel +66(0)616852307, Email: chaisiri.a@cmu.ac.th

What happens if new information becomes available during the study?

Sometimes during a study, new information becomes available about the treatment being studied. If this happens, the research team will tell you and discuss whether you want to continue in the study. If you decide to stop taking part in the study your usual care will continue. If you decide to continue in the study you may be asked to sign an updated consent form. If we think you should withdraw from the study, we will explain the reasons and arrange for your care to continue.

What happens when the study stops?

Very occasionally a study is stopped early. If this happens, the reasons will be explained to you.

Tissue studies:

What will happen to the samples I give?

Blood samples will be used to measure HbA1c and lipids, coordinating where possible with the annual routine tests offered to patients to reduce duplication. Blood will be drawn by a trained phlebotomist when participants come for interview and sent to laboratory for analysis. Data will be linked to the participant information using a unique respondent ID, which will be assigned to all study participants.

Blood samples will be sent to a laboratory within the Chiang Mai area. The results of the blood tests will be provided to your health care professional who will discuss with you if there are any issues.

We may use some of the samples collected for future studies. These will be anonymised when stored, and all future research using these samples will be reviewed by an independent ethics committee.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 4 of 5

CONSENT FORM FOR PARTICIPANT AND REPRESENTATIVE

Title of Project: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Name of PI/Researcher responsible for project: Chaisiri Angkurawaranon

1
2
3
4
5

Statement	Please initial or thumbprint* each box
I confirm that I have read and understood the information sheet dated 08.10.2018 (version 1.0) for the above named study. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.	
I understand that my consent is voluntary and that I am free to withdraw this consent at any time without giving any reason and without my medical care or legal rights being affected.	
I understand that relevant sections of my/the participant's medical notes and data collected during the study may be looked at by authorised individuals from Chiang Mai University, where it is relevant to my taking part in this research. I give permission for these individuals to have access to these records.	
I understand that data about/from me/the participant may be shared via a public data repository or by sharing directly with other researchers, and that I will not be identifiable from this information	
I understand that the tissue sample collected from me will be used to support other research in the future, and may be shared anonymously with other researchers, for their ethically-approved projects	
I give permission for a copy of this consent form, which contains my personal information, to be made available to the Trial Coordinating Centre for monitoring purposes only.	
I agree to my health care provider being informed of my participation in the study.	
I agree to me taking part in the above named study.	

--	--	--

Printed name of participant/Representative Signature of participant/Representative Date
(or thumbprint/mark if unable to sign)

--	--	--

Printed name of person obtaining consent Signature of person obtaining consent Date

The participant is unable to sign. As a witness, I confirm that all the information about the trial was given and the participant/representative consented to taking part *(*only required if the participant/representative is unable to read or write)*

--	--	--

Printed name of impartial witness* Signature of impartial witness* Date

56
57
58
59
60

A copy of this informed consent document has been provided to the participant.

Centre Number:
Study Number:
Participant Identification Number:

แบบขอรับความยินยอมเข้าร่วมโครงการ (Consent ข้อมูลสำหรับผู้ป่วย)

ชื่อโครงการศึกษาวิจัย : “การพัฒนาทางออกเพื่อการขยายการบริการที่เพิ่มความสามารถในการดูแลตนเองของผู้ที่เป็นเบาหวานในประเทศไทย”

หมายเลขโครงการศึกษาวิจัย : FAM-2561-05594

ผู้ให้ทุนสนับสนุนการวิจัย : สำนักงานคณะกรรมการส่งเสริมวิทยาศาสตร์ วิจัยและนวัตกรรม (สกสว.)

แพทย์ผู้วิจัยหลัก : อ.ดร.นพ.ชัยสิริ อังกระวรรณนท์

ท่านได้รับการเชิญให้เข้าร่วมการศึกษานี้เนื่องจากท่านได้รับการวินิจฉัยว่าเป็นโรคเบาหวานที่เพิ่งได้รับการวินิจฉัยมาไม่เกิน 1 ปี หรือเป็นผู้ป่วยเบาหวานที่ยังไม่สามารถควบคุมน้ำตาลได้ ขอให้ท่านกรุณาอ่านข้อมูลข้างล่างก่อน (หรือผู้วิจัยได้อ่านให้ท่านรับทราบ) หากท่านมีข้อข้องใจใดๆ เกี่ยวกับการศึกษานี้ และสิทธิของท่าน กรุณาซักถามจากแพทย์ผู้ทำการศึกษานี้ หรือ ผู้ช่วยแพทย์ที่ทำการศึกษานี้ ซึ่งจะเป็นผู้สามารถให้ความกระจ่างแก่ท่านได้ หากท่านตัดสินใจเข้าร่วมการศึกษานี้ ท่านจะได้รับเอกสารข้อมูลสำหรับผู้เข้าร่วมโครงการวิจัยและสำเนาใบยินยอมที่ท่านเซ็นชื่อกำกับเก็บไว้ 1 ฉบับ

การศึกษานี้เกี่ยวกับเรื่องอะไร

เนื่องจากในปัจจุบันนี้มีผู้ป่วยเป็นโรคเบาหวานจำนวนมากขึ้น และพบว่าผู้ป่วยเป็นโรคเบาหวานนี้สัมพันธ์กับภาวะแทรกซ้อนทางสุขภาพมากมาย เพื่อให้เป็นประโยชน์ต่อการพัฒนาการดูแลรักษาผู้ป่วยเบาหวานในอนาคต ผู้วิจัยจึงสนใจที่จะศึกษาว่าการเป็นโรคเบาหวานนั้นสัมพันธ์กับการเปลี่ยนแปลงระดับชีวภาพในร่างกายอย่างไร โดยผ่านการตรวจเลือดและอุจจาระ และเพื่อศึกษาว่าการจัดทำโครงการให้ความรู้ในการดูแลตนเองของผู้ป่วยเบาหวานโดยใช้สื่อมัลติมีเดียเข้าช่วยเหลือมีผลลัพธ์ของการรักษาที่ดีขึ้นได้หรือไม่ การศึกษานี้จะรวบรวมผู้ป่วยประมาณ 600 ราย จากโรงพยาบาลชุมชนที่ให้การรักษาแบบปฐมภูมิ ในจังหวัดเชียงใหม่ และ ลำปาง

ท่านจะต้องปฏิบัติตัวอย่างไร

หากท่านตัดสินใจเข้าร่วมการศึกษานี้ท่านจะถูกขอร้องให้เซ็นชื่อลงในใบยินยอมท่านจะได้รับการซักประวัติเกี่ยวกับโรคประจำตัวและการรักษาที่ได้รับ ได้ตรวจร่างกาย และการเจาะเลือด

เพื่อเป็นข้อมูลเริ่มต้นก่อนการรักษา โดยทั้งนี้ท่านจะได้รับการดูแลตามปกติควบคู่ไป

จากนั้นท่านจะได้รับการอบรมเพื่อพัฒนาศักยภาพในการดูแลตนเองในโรคเบาหวานของท่านโดยทีมดูแลสุขภาพ ซึ่งหน่วยบริการของท่านจะถูกสุ่มให้อยู่ 1 ใน 3 กลุ่ม อันได้แก่ กลุ่มทดลอง1 กลุ่มทดลอง2 และกลุ่มควบคุม โดยทั้ง 3 กลุ่มจะได้รับข้อมูลและการดูแลพื้นฐานเช่นเดียวกัน แต่แตกต่างกันในรูปแบบของการให้การอบรมในการดูแลตนเองของผู้ป่วยเบาหวาน ซึ่งจะใช้เวลาไม่นาน ไม่เกิน ครึ่งวัน โดย

- กลุ่มที่ 1 อบรมโดยบุคลากรทางการแพทย์ พยาบาล หรือ เจ้าหน้าที่สาธารณสุข
- กลุ่มที่ 2 อบรมโดยกลุ่มเพื่อนช่วยเพื่อนหรืออสม.ที่ผ่านการฝึกอบรมด้านการเพิ่มศักยภาพในการดูแลตนเองในโรคเบาหวาน
- กลุ่มที่ 3 ได้รับความรู้จากการดูแลตามมาตรฐานของกระทรวงสาธารณสุข

ซึ่งทั้งสามกลุ่ม จะมีการนัด หรือ ติดตาม ความก้าวหน้าพฤติกรรม的自我ดูแลตนเอง ทุกๆ 1-3 เดือน

การติดตามผลเลือดและตอบแบบสอบถาม จะถูกทำในครั้งแรกข้างต้น และอีก 2 ครั้ง คือ ที่ 6 เดือนและที่ 12 เดือนนับจากครั้งแรกที่อบรม โดยทั้ง 3 ครั้ง ท่านจะถูกเจาะเลือดเพื่อส่งตรวจปริมาตรทั้งสิ้นครั้งละ 40 มิลลิลิตร

ความเสี่ยงจากการเข้าร่วมการวิจัยนี้

ความเสี่ยงจากการเจาะเลือด - ท่านอาจรู้สึกหน้ามืด เป็นลม ปวดบริเวณที่เจาะ หรือมีจ้ำเลือดบริเวณที่เจาะ มีความเสี่ยงน้อยมากที่จะเกิดการติดเชื้อจากการเจาะเลือดเพราะเราใช้เข็มเจาะเลือดที่ปราศจากเชื้อและใช้ครั้งเดียวทิ้ง การเจาะเลือดทั้งหมดอยู่ในสถานพยาบาล และหากมีปัญหาจะได้รับการดูแลทันที

ท่านจะได้ประโยชน์อะไรจากการศึกษา

ท่านจะได้รับความรู้เพื่อนำไปใช้ในการดูแลตนเองเพื่อควบคุมโรคเบาหวานของท่าน และผลสรุปที่ได้จากการศึกษานี้จะเป็นประโยชน์ต่อผู้ป่วยรายอื่นในอนาคต

ค่าใช้จ่ายในการเข้าร่วมวิจัย

ท่านจะไม่ต้องเสียค่าใช้จ่ายเพิ่มเติมเกี่ยวกับการวิจัยนอกเหนือจากค่ารักษาปกติที่ควรจะเป็นซึ่งท่านสามารถใช้สิทธิในการเบิกจ่ายได้ตามสิทธิการรักษาปกติของท่าน

ค่าตอบแทน

สำหรับการมาตรวจติดตามที่เพิ่มจากการตรวจรักษาตามปกติ จำนวน 5 ครั้ง ซึ่งจะมีการตรวจเลือด รวม 3 ครั้ง ท่านจะได้รับค่าเดินทางและค่าเสียเวลาครั้งละ 100 บาท (รวม 500 บาทต่อคน ตลอดระยะเวลาโครงการ 1 ปี)

หากท่านได้รับบาดเจ็บจากการเข้าร่วมการศึกษาวิจัย

หากท่านได้ปฏิบัติตามคำแนะนำของแพทย์ผู้วิจัยแล้ว กระบวนการต่าง ๆ ในการวิจัยทำให้ท่านได้รับบาดเจ็บ เมื่อผู้วิจัยได้รับแจ้งจากท่าน ท่านจะได้รับการส่งต่อเพื่อรักษาภาวะดังกล่าวทันที

ท่านจะอย่างไรหากท่านไม่ต้องการเข้าร่วมการศึกษาวิจัย หรือเปลี่ยนใจระหว่างร่วมศึกษาวิจัย

ท่านไม่จำเป็นต้องเข้าร่วมการศึกษาวิจัยนี้หากท่านไม่สมัครใจ หลังจากท่านตัดสินใจจะเข้าร่วมการศึกษาแล้ว ท่านสามารถจะถอนตัวได้ตลอดเวลา การตัดสินใจของท่านจะไม่มีผลต่อการรักษาในอนาคต หรือการดูแลอื่นใดหากท่านไม่ต้องการเข้าร่วมการศึกษาหรือต้องการหยุดการศึกษา ณ เวลาใดก็ตาม แพทย์ของท่านจะอธิบายให้ทราบถึงการรักษาอื่น ๆ ซึ่งเป็นทางเลือกที่มีอยู่ขณะนี้ ผู้วิจัยอาจจะตัดสินใจยกเลิกท่านจากการศึกษา หากเห็นว่าจะเป็นประโยชน์สำหรับท่านมากกว่า

ใครจะรู้บ้างว่าท่านเข้าร่วมการศึกษานี้

แพทย์ประจำตัวท่าน (แพทย์เวชปฏิบัติทั่วไป) ควรจะได้รับทราบว่าท่านตัดสินใจเข้าร่วมการศึกษาวิจัยนี้ ข้อมูลของท่านที่ถูกบันทึกไว้ระหว่างการศึกษานี้ เช่นเดียวกับข้อมูลที่เกี่ยวข้องจากแฟ้มเวชระเบียนของโรงพยาบาล คลินิก บริษัทฯ หรือข้อมูลอื่น ๆ จะถูกเก็บไว้เป็นความลับตลอดเวลา คณะกรรมการจริยธรรมการวิจัยสามารถที่จะขอตรวจสอบข้อมูลเหล่านี้ได้ โดยข้อมูลเหล่านี้จะยังเก็บรักษาไว้เป็นเรื่องลับเฉพาะ

การปกป้องรักษาข้อมูล : ข้อมูลใดบ้างที่จะถูกเก็บรวบรวมไว้จากการศึกษานี้

ข้อมูลที่ถูกเก็บรวบรวมนั้นจะมีเฉพาะในส่วนที่เกี่ยวข้องกับการศึกษาเพื่อวัตถุประสงค์ทางการวิจัยทางการแพทย์ โดยจะไม่มีการอ้างถึงข้อมูลส่วนตัวของท่าน อันได้แก่ชื่อท่าน ในรายงานหรือวารสารใด ๆ หากท่านตกลงใจเข้าร่วมการศึกษา ท่านยินยอมที่จะไม่จำกัดการให้ข้อมูลที่เป็นส่วนตัวยกเว้นในกรณีที่ขัดต่อสิทธิส่วนบุคคลภายใต้กฎหมายคุ้มครองสิทธิส่วนบุคคล

หากท่านมีคำถามเกี่ยวกับการศึกษานี้ท่านสามารถติดต่อใครได้บ้าง

หากท่านมีคำถามหรือมีความวิตกกังวลเกี่ยวกับการศึกษาวิจัยนี้ หรือสงสัยว่าท่านกำลังได้รับบาดเจ็บจากการเข้าร่วมการวิจัยนี้ กรุณาติดต่อ คุณกุลญาภา อยู่นัด ได้ที่ ภาควิชาเวชศาสตร์ครอบครัว โทรศัพท์ที่ทำงาน 053-936362 (ในเวลาราชการ)

ส่วนแสดงความยินยอม

โดยการลงนามในหนังสือยินยอมฉบับนี้ ท่านยอมรับว่าได้อ่านเอกสารฉบับนี้แล้วและได้รับคำอธิบายเกี่ยวกับการศึกษาวิจัยนี้ รวมถึงได้รับคำตอบเกี่ยวกับข้อสงสัยต่าง ๆ ที่ท่านมีจากผู้วิจัยแล้ว

1
2
3
4
5 ท่านตกลงใจที่จะเข้าร่วมในการศึกษาวิจัยนี้ และมีสิทธิ์ที่จะถอนตัวจากการศึกษาวิจัยนี้ได้ทุกเมื่อ โดยไม่มี
6 ผลต่อการรักษาในอนาคต โดยการลงนามนี้ท่านไม่ได้สละสิทธิ์ใด ๆ ที่พึงมีทางกฎหมาย
7
8 ทั้งนี้ ท่านยินยอมที่จะเข้ารับการอบรมในโครงการวิจัย ตอบแบบสอบถามและ
9
10
11
12
13

14 ลายมือชื่ออาสาสมัคร _____ วัน-เดือน-ปี _____

15
16 (_____)
17
18

19
20 ลายมือชื่อเจ้าหน้าที่ผู้ให้ข้อมูล _____ วัน-เดือน-ปี _____

21 ณ สถานพยาบาล

22
23 (_____)
24
25

26 พยาน _____ วัน-เดือน-ปี _____

27
28
29 (_____)
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	Page/Line number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Line 357
	2b	All items from the World Health Organization Trial Registration Data Set	-
Protocol version	3	Date and version identifier	Lines 357-358
Funding	4	Sources and types of financial, material, and other support	Lines 344-346
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page 1 and Lines 338-342
	5b	Name and contact information for the trial sponsor	Lines 359-360
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Lines 344-353

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Lines 322-326
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Page 4 and 5
	6b	Explanation for choice of comparators	Lines 99-103
Objectives	7	Specific objectives or hypotheses	Lines 92-94, 217-226
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Lines 98-103
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Lines 105-117
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Lines 119-129

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Lines 157-187
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	n/a
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Lines 192-197
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Lines 217-229
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Page 9-11

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Lines 140-148
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Lines 131-138
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	n/a
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial	
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Lines 228 Table 2
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Lines 264
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Lines 277-285
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Lines 277-285

	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	n/a
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	Lines 322
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Lines 364

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Lines 319-320
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Lines 150-155
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Lines 150-155
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Lines 362-363
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Lines 348-349
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Lines 328-336
	31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Attached
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand (DSME-T): A Cluster Randomized Trial Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-036963.R2
Article Type:	Protocol
Date Submitted by the Author:	30-Aug-2020
Complete List of Authors:	Angkurawaranon, Chaisiri; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Papachristou Nadal, Iliatha; London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health Mallinson, Poppy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology Pinyopornpanish, Kanokporn; Chiang Mai University, Department of Family Medicine, Faculty of Medicine Quansri, Orawan; Mahidol University Rerkasem, Kittipan ; Chiang Mai University, Department of Surgery, Faculty of Medicine, Chiang Mai University; Chiang Mai University, Research Institute for Health Sciences Srivanchakorn, Supattra; Royal Thai Government Ministry of Public Health Techakehakij, Win; Lampang Hospital Wichit, Nutchath; Surat Thani Rajabhat University Pateekhum, Chanapat; Chiang Mai University Hashmi, Ahmar; Chiang Mai University, Department of Family Medicine Hanson, Kara; London School of Hygiene and Tropical Medicine Khunti, Kamlesh; University of Leicester, Department of Health Sciences Kinra, Sanjay; London School of Hygiene and Tropical Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Evidence based practice, Diabetes and endocrinology, General practice / Family practice
Keywords:	DIABETES & ENDOCRINOLOGY, EDUCATION & TRAINING (see Medical Education & Training), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand**
4
5 **(DSME-T): A Cluster Randomized Trial Study Protocol**
6

7 Chaisiri Angkurawaranon^{1*}, Iliatha Papachristou Nadal^{2,3}, Poppy Alice Carson Mallinson²,
8 Kanokporn Pinyopornpanish¹, Orawan Quansri⁴, Kittipan Rerkasem^{5,6}, Supattra Srivanichakorn⁷,
9 Win Techakehakij⁸, Nutchath Wichit⁹, Chanapat Pateekhum¹, Ahmar Hashmi¹, Kara
10 Hanson¹⁰, Kamlesh Khunti¹¹, Sanjay Kinra²
11
12
13
14
15

16
17 **Author affiliations**
18

19 ¹ Department of Family Medicine, Faculty of Medicine, Chiang Mai University
20

21 ² Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
22 Medicine
23

24 ³ Psychological Medicines, King's College London
25

26 ⁴ ASEAN Institute for Health Development, Mahidol University
27

28 ⁵ Department of Surgery, Faculty of Medicine, Chiang Mai University
29

30 ⁶ NCD Centre of Excellence, Research Institute for Health Sciences, Chiang Mai University
31

32 ⁷ Department of Disease Control, Ministry of Public Health
33

34 ⁸ Department of Social Medicine, Lampang Hospital
35

36 ⁹ Faculty of Nursing, Suratthani Rajabhat University
37

38 ¹⁰ Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine
39

40 ¹¹ Diabetes Research Center, University of Leicester
41
42
43
44
45
46
47
48

49 **Word count:** 3769 excluding references
50

51 **Corresponding author:** Chaisiri Angkurawaranon, Department of Family Medicine, Faculty of
52 Medicine, Chiang Mai University, email: chaisiri.a@cmu.ac.th
53
54
55
56
57
58

1 **ABSTRACT**

2 **Introduction** Type 2 diabetes mellitus is amongst the foremost health challenges facing policy
3 makers in Thailand as its prevalence has more than tripled over the last two decades, accounting
4 for considerable death, disability and healthcare expenditure. Diabetes Self-Management
5 Education (DSME) programmes show promise in improving diabetes outcomes, but this is not
6 routinely utilised in Thailand. This study aims to test a culturally-tailored DSME model in
7 Thailand, using a 3-arm cluster randomised controlled trial comparing a nurse-led model, a peer-
8 assisted model, and standard care. We will test which model is effective and cost effective to
9 improve cardiovascular risk and control of blood glucose among people with diabetes.

10
11 **Methods and analysis** 21 primary care units in northern Thailand will be randomised to one of
12 three interventions, enrolling a total of 693 patients. The primary care units will be randomised
13 (1:1:1) to participate in a culturally-tailored DSME intervention for 12 months. The three-arm
14 trial design will compare effectiveness of nurse-led, peer-assisted (Thai village health volunteers)
15 and standard care. The primary trial outcomes are changes in haemoglobin A1c and
16 cardiovascular risk score. A process evaluation and cost effectiveness evaluation will be
17 conducted to produce policy relevant guidance for the Thai Ministry of Public Health. The
18 planned trial period will start in January 2020 and finish October 2021.

19
20 **Ethics and dissemination** Ethical approval has been obtained from Thailand and the UK. We
21 will share our study data with other researchers, advertising via our publications and web
22 presence. In particular, we are committed to sharing our findings and data with academic
23 audiences in Thailand and other low- and middle-income countries.

1
2
3 24 **Trial registration number:**
4

5 25 ClinicalTrials.gov ID NCT03938233
6
7

8 26 **Strengths and limitation of this study**
9

- 10 27 • A three-arm cluster randomized controlled trial to evaluate clinical and cost-effectiveness
11
12 28 of a culturally tailored DSME under two alternative modes of delivery (nurse-led and
13
14 29 peer-assisted) will provide policy makers with options for scalability.
15
16
17 30 • A culturally-tailored DSME programme has been developed with input from stakeholders
18
19 31 (policy makers, clinicians, nurses, village health volunteers and people with diabetes).
20
21
22 32 • A series of short films has been developed to introduce key topics, as there is increasing
23
24 33 recognition that films are a highly efficient medium for communicating information,
25
26 34 particularly in low literacy settings
27
28
29
30
31
32
33
34
35
36
37

38 INTRODUCTION

39 Type 2 diabetes mellitus (hereto referred to as diabetes) is amongst the foremost health
40 challenges facing policy makers in Thailand. Its prevalence has more than tripled over the last
41 two decades to an estimated 4 million adults (age adjusted prevalence 7.1%) living with diabetes
42 in 2015.^{1,2} Diabetes is associated with several macrovascular (e.g. ischaemic heart disease) and
43 microvascular complications (e.g. nephropathy, retinopathy, neuropathy, and foot disease),
44 which primarily account for the considerable death and disability (of which diabetes is the 5th
45 leading cause in Thailand)³. In addition, diabetes in Thailand causes a two-fold increase in
46 healthcare expenditure and significant loss of economic productivity—of both people with
47 diabetes and their carers.¹

48 The complications of diabetes can be largely prevented or delayed through lifestyle change and
49 medication when necessary, and regular screening for early detection and management of
50 complications to control risk factors such as blood glucose, lipids and blood pressure.^{4,5} Under
51 Thailand's universal health coverage, nearly everyone diagnosed with diabetes receives timely
52 medical care (>97%) and has access to screening. Yet, surveys suggest that only about half of the
53 people with diabetes achieve optimal control of risk factors or receive annual screening for
54 microvascular complications (53-60%).^{1,6} Limited data support a lack of engagement and self-
55 management skills among those diagnosed with diabetes as the main underlying reasons for this.⁷
56 Successful management of diabetes involves a considerable degree of self-management. People
57 with diabetes need to adhere to multiple behaviours, including healthy lifestyles, regular
58 monitoring and medication, problem-solving and healthy coping strategies. In this, they are
59 greatly supported by diabetes self-management education (DSME), defined as 'a collaborative
60 and ongoing process intended to facilitate the development of knowledge, skills, and abilities
61 that are required for successful self-management of diabetes'.⁸ Evidence from over 100 studies,

1
2
3 62 including many randomised controlled trials conducted predominantly in high-income countries,
4
5 63 suggests that DSME programmes are associated with improvements in a range of behavioural
6
7 64 outcomes (knowledge, behaviours, self-efficacy, psychosocial), and clinical outcomes
8
9
10 65 (physiological risk factors, screening for complications, quality of life),^{9,10} and are cost-
11
12 66 effective.¹¹ Therefore, DSME programmes are recommended by most clinical guidelines.⁸
13
14
15 67 However, there is considerable heterogeneity in the effectiveness of DSME programmes^{9,10}.
16
17 68 Programmes that are more effective usually offer more than 10 hours of contact between trainers
18
19 69 and patients, incorporate behavioural approaches and provide longer-term support mechanisms.
20
21 70 However, providing intensive and sustained support has cost implications, resulting in ongoing
22
23 71 efforts to identify more cost-efficient ways to deliver DSME, notably through use of lay health
24
25 72 workers or peer educators, such as Thai village health volunteers (VHV).
26
27
28 73 Peers can support sustained changes in complex health behaviours by providing assistance in
29
30 74 daily management, social and emotional support, linkage to clinical care, and ongoing
31
32 75 availability of support.^{12,13} Unlike the educational/psychological framework of professional
33
34 76 support, peer support operates on a social support framework. Although traditionally restricted to
35
36 77 those with experience of disease, the definition of peers has been expanded to include other non-
37
38 78 professionals with a close relationship with the community (e.g. VHV).¹⁴ However, despite
39
40 79 widespread interest, empirical data on effectiveness of peers in supporting behaviour change in
41
42 80 chronic diseases, including diabetes, is limited and inconsistent.^{15,16} In an earlier review, the
43
44 81 World Health Organisation did not find sufficient evidence to recommend peer support
45
46 82 programmes as a policy option for diabetes management in LMICs.¹⁷ Whereas many studies on
47
48 83 the effectiveness of DSME programmes come from high-income countries (HIC), there is a
49
50 84 dearth of data from LMIC settings on cost-effectiveness, acceptability and potential adverse
51
52
53
54
55
56
57
58
59
60

1
2
3 85 consequences of peer support programmes, as well as optimal strategies for mobilising and
4
5 86 integrating peers in diabetes care pathways.^{13,18-19}
6

7
8 87 In the Thai healthcare system, structured DSME is not routinely available. While several small-
9
10 88 scale studies from Thailand have demonstrated that DSME can strengthen self-management of
11
12 89 diabetes, negative perceptions of educational programmes and concerns about the burden on
13
14 90 existing staff time and costs, have so far prevented the introduction of DSME.^{1,19} However,
15
16 91 recent policy developments in Thailand are supportive of DSME introduction, if a scalable
17
18 92 model can be found. We therefore hypothesise that a nurse-led and/or peer-assisted model for
19
20 93 DSME delivery will be effective in improving blood glucose among people with diabetes, with
21
22 94 the peer-assisted model being the more scalable option for the Thai healthcare system. We
23
24 95 propose to evaluate this through a three-arm cluster randomised controlled trial.
25
26
27
28
29
30

31 97 **METHODS AND ANALYSIS**

32 33 98 **Study design**

34
35 99 This study is an MRC complex intervention,²⁰ three-arm cluster randomised controlled trial.
36
37 100 Primary care units from within two provinces: Chiang Mai and Lampang will be randomised for
38
39 101 patients to receive either the nurse-led or peer-assisted DSME intervention or standard care (brief
40
41 102 education session by a nurse). Assessments will be undertaken at baseline, 6- and 12-month
42
43 103 follow up. A process and cost-effective evaluation will also be conducted.
44
45
46
47
48

49 105 **Setting and Participant Selection**

50
51 106 Potential participants requiring a DSME intervention will be recruited from 21 primary care units
52
53 107 in Chiang Mai (7 primary care units) and Lampang provinces (14 primary care units) in northern
54
55
56
57
58
59
60

1
2
3 108 Thailand. Chiang Mai is a province of over 1.4 million people with 24 district hospitals and
4
5 109 about 250 primary care units. Lampang is a province of approximately 700,000 people with 12
6
7
8 110 district hospitals and about 140 primary care units. While diabetes is diagnosed at tertiary and
9
10 111 district hospitals, it is managed at the primary care unit health centres, which are served by a full-
11
12 112 time nurse (doctor visits weekly), and 10-15 village health volunteers (VHV) linking patients in
13
14 113 the community.

15
16
17 114 From clinical records, we will recruit all new referrals for diabetes management and patients
18
19 115 with uncontrolled diabetes diagnosed in the past 3 years at the 21 primary care units over a 9-
20
21 116 month period (N=693). Posters and information sheets will be used to provide necessary, trial-
22
23 117 related information to prospective participants (Figure 1).

24
25
26 118

27
28 119 Participants presenting to one of the 21 primary care units will be included if they are:

- 29
30
31 120 1. Over 18 years of age with a new referral for type 2 diabetes management;
32
33 121 2. Over 18 years of age with uncontrolled diabetes ($HbA1c > 7\%$) within the first three
34
35 122 years of diagnosis;
36
37
38 123 2. Willing and able to attend educational group meetings; and
39
40 124 3. Available for 6- and 12-month follow-up visits

41
42 125 Participants will be excluded if they:

- 43
44 126 1. Have advanced diabetic complications such as diabetic nephropathy, diabetic
45
46 127 retinopathy, or amputations; or if they are pregnant as patients with these conditions and
47
48 128 co-morbidities are usually referred to secondary care facilities for treatment in Thailand
49
50
51 129 and not often managed in primary care where this trial is conducted.
52
53
54 130 2. Have learning disabilities, dementia or active severe mental illness; or

1
2
3 131 3. Lack the capacity to give voluntary, informed consent.
4
5
6 132

7
8 133 **Randomisation**

9
10 134 Stratified by province, 21 primary care units (7 from Chiang Mai and 14 from Lampang) will be
11
12 135 randomised to provide one of three interventions: (1) nurse-led DSME; (2) nurse-led DSME with
13
14 136 peer assistance (provided by Thai village health volunteers, VHV); or (3) standard care (brief
15
16 137 education session by a nurse), resulting in seven primary care units in each arm of the study. All
17
18 138 primary care units follow protocols for diabetes management as outlined by national guidelines.
19
20 139 Stratification by province will minimise any variation in practice between the different primary
21
22 140 care units.
23
24
25
26 141

27
28 142 **Sample size calculation**

29
30 143 The trial is powered to detect a difference in HbA1c of 0.6% (SD 1.5%) between control and
31
32 144 intervention arms, based on the effect size of 0.6% noted in a previous diabetes management
33
34 145 study in Thailand²¹, and the fact that an increase in HbA1c of ~0.5% was associated with
35
36 146 increased mortality among people with diabetes²². An ICC between primary care units of 0.02
37
38 147 was assumed based on a similar study which found that the intraclass correlation for HbA1c at
39
40 148 three years was 0.02 (95% confidence interval 0.00 to 0.08)²³. Allowing for a loss-to-follow up
41
42 149 rate of 20%, 693 participants are needed from 21 primary care units (7 in each trial arm arm) to
43
44 150 achieve 80% power at 2.5% significance level.
45
46
47
48
49

50 151

51
52 152 **Informed consent**
53
54
55
56
57
58
59
60

1
2
3 153 Written informed consent will be obtained from all study participants in Thai before any study
4
5 154 procedures are undertaken including enrolment, intervention allocation, follow-up interviews and
6
7
8 155 blood draws. Local research assistants will explain the study to patients using the patient
9
10 156 information sheet (supplementary file). The right of the patient to refuse to participate without
11
12 157 giving reasons will be respected.
13
14
15 158

17 159 **Intervention description and delivery**

19 160 The DSME programme has been developed using a structured process. This included a desk and
20
21 161 literature review and focus groups with local nurses and VHV to develop a paper prototype of
22
23 162 the intervention, including a hypothesised pathway of action (e.g. common-sense model of
24
25 163 illness, empowerment, discovery learning, social learning, and social support) and a training
26
27 164 manual for nurses and VHV. In addition, seven brief films (5-6 minutes long) have been
28
29 165 developed and have been used to trigger discussions on key topic areas during DSME
30
31 166 intervention meetings covering such topics as medical adherence, dietary recommendation,
32
33 167 physical activity and stress management. Films will be used in the intervention as they are
34
35 168 increasingly recognised as a highly effective medium for improved recall when communicating
36
37 169 large amounts of information, particularly in low literacy settings.²⁴ Films will be in the local
38
39 170 language and use local people.
40
41
42
43
44
45 171

47 172 Our DSME programme will consist of four modules. Module 1 covers the general overview of
48
49 173 diabetes, treatment targets and goal setting. Module 2 covers diet and nutrition. Module 3 covers
50
51 174 physical activity and exercise, while module 4 covers stress management and mental health.
52
53
54
55
56
57
58
59
60

1
2
3 175 Each module takes approximately 1.5 hours. Each participant is given an information and self-
4
5 176 assessment booklet which covers all content and materials for the four modules.
6
7
8 177 In addition to routine care, in the nurse-led arm, the nurse will deliver the DSME to groups of 5-
9
10 178 10 participants per session within the first months after enrolment. The participants in the nurse-
11
12
13 179 led arm will also be given a refresher session going over all 4 modules again at 6 months after
14
15 180 enrolment. For the peer-assisted arm, a VHV will participate as an assistant to the nurse in the
16
17 181 first DSME session. However, the VHV will lead the refresher course at 6 months. In addition,
18
19 182 participants in the peer-assisted arm will receive monthly contact with the VHV either via a
20
21
22 183 home visit or telephone call. During these brief 15-20 minute monthly contacts, VHV will ask
23
24 184 about the progress made, providing encouragement if plans for self-management are being
25
26 185 followed or discussing ways to overcome barriers and set new goals if obstacles are identified.
27
28
29 186 Contents of the three trial arms are summarized in Table 1.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

187 **Table 1:** Summary of DSME delivery in the three trial arms

Month	Routine care	Nurse-led DSME	Peer-assisted DSME*
0	Individual session	Nurse provides DSME (4 modules)	Nurse provides DSME (4 modules) with VHV to assist the sessions
6	Individual session	Refresher course (4 modules) provided by nurse	Refresher course (4 modules) led by VHV
12	Outcome assessment	Outcome assessment	Outcome assessment

188 * participants in the peer-assistant arm will additionally receive monthly contact with the VHV
 189 either via a home visit or telephone call.

190
 191 The intervention will be piloted at four community primary care units with four nurses and four
 192 VHV who will be trained to deliver the DSME programme to groups of 5-10 persons with
 193 diabetes. This will allow for refining the intervention, ensuring data collection can be completed
 194 as specified, and to check our assumptions and processes for the trial. For the main trial, a two-
 195 day workshop will be held such that at least one nurse and one VHV from each primary care unit
 196 will be trained by the Thai research team to deliver the DSME programme at the community
 197 primary care unit or neighbourhoods as appropriate. The trial coordinator will conduct periodic
 198 site visits as additional training as requested and a line of communication will be established
 199 between the research team and each site to answer any issues which may arise.

200

1
2
3 201 A process evaluation using qualitative methods will be conducted during the trial period and at
4
5 202 the end of the study. Observations including video recordings of intervention delivery will be
6
7 203 made. We plan to conduct 5-10 focus groups among providers (nurses and VHV) to explore
8
9 204 healthcare professionals' perspectives regarding their experience and implementation of the
10
11 205 DSME programme, including views on the cultural transferability of DSME and scalability to
12
13 206 the Thai context. In addition, we plan to conduct 20 structured interviews with patients. These
14
15 207 evaluations will help assess intervention delivery (fidelity, dose and reach), clarify causal
16
17 208 mechanisms (those hypothesised by theory of change developed within the project or emergent
18
19 209 mechanisms identified), and detail contextual factors (barriers, facilitators) associated with
20
21 210 variation in outcomes.²⁵ The process evaluation will also consist of one-to-one interviews with
22
23 211 clinicians and policy makers and direct observations of patients. Data for economic evaluations
24
25 212 (resource usage and quality of life using EQ-5D²⁶) will be obtained prospectively alongside the
26
27 213 trial.
28
29
30
31
32

214

215 **Standard care**

216 Patients in the control group will receive standard care in the form of a brief didactic educational
217 session at the time of diagnosis of diabetes and during routine clinic visits at 6 months.²⁷

218

219 **Study outcomes**

220 The two primary outcomes of the intervention are a difference in trial arms at one-year follow-up
221 in HbA1c and cardiovascular risk score. There is a growing recognition of the importance of
222 combining tight glycaemic control with reduction in other cardiovascular risk factors for
223 prevention of or reduction in complications.⁵ The cardiovascular risk will be estimated by the

224 Thai cardiovascular risk score model, which estimates the risk of dying from any cardiovascular
 225 disease over 10 years based on age, gender, smoking habits, total cholesterol and systolic blood
 226 pressure, as it has been calibrated for use in a Thai population.²⁸

227 Additional secondary outcomes include changes at one year for biological, physical,
 228 psychosocial, lifestyle and intervention-related measures, as described in Table 2.

229

230 **Table 2:** Summary of primary and secondary outcome measures

Primary outcomes	Measures or questionnaires
Haemoglobin A1c levels (HbA1c)	HbA1c will measure the average blood glucose (sugar) levels over the past two to three months
Thai Cardiovascular risk score	Estimates the risk of dying from any cardiovascular disease over 10 years based on age, gender, smoking habits, total cholesterol and systolic blood pressure.
Secondary outcomes	Measures or questionnaires
Biological and physical measures	Body weight, Body Mass Index; BMI, Blood lipids (Total, LDL-C HDL, triglycerides), waist circumference, blood pressure, fasting blood glucose
Quality of life	WHOQOL-BREF. A 26 item questionnaire developed by WHO to assess quality of life in adults ²⁹
	The European Quality of life questionnaire; EuroQol EQ-5D 5L ²⁶ EQ-5D is a quality of life measure that includes five quality of life questions on mobility, self-care, usual activity, pain,

	anxiety/depression and a scale of 0 to 100 on how the person is feeling on that day.
Depression	Hospital Anxiety and Depression Scale; HADS ³⁰ HADS measures depression and anxiety that will address psychological change with a scale from 0 to 3.
Stress	Perceived Stress Questionnaire; PSS ³¹ PSS is a psychological instrument for measuring the perception of stress. Ten items with a scale from 1 to 4.
Physical activity	International Physical Activity Questionnaire; IPAQ ³² Short form IPAQ is an assessment of physical activity comprising of seven questions. There are two forms of output from scoring the IPAQ. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET-minutes a week). MET-minutes represent the amount of energy expended carrying out physical activity.
Diabetes knowledge and skills	Brief diabetes Illness Perception Questionnaire; B-IPQ ³³ . B-IPQ has nine components of which the first five questions assess the cognitive representation of illness perception, two of the questions assess the emotional representation, one item assesses comprehensibility and one item on the root cause of the illness
	Diabetes Self-Management Education and Support; DMSES ³⁴ . DMSES is one of the most widely used scale in measuring self-efficacy in type 2 diabetes management. The Thai-DMSES has

	<p>twenty questions which has been demonstrated to have good psychometric properties³⁵</p>
	<p>Summary of Diabetes Self-Care Activities questionnaire SDSCA³⁶</p> <p>SDSCA is a diabetes self-care activities questionnaire focusing on general diet, diabetes-specific diet, physical activity, blood-glucose testing, foot care, and smoking.</p>
<p>Satisfaction with intervention</p>	<p>Chronic Illness Resources Survey (CIRS)³⁷</p> <p>CIRS is a questionnaire to represent patient's received support.</p> <p>Individual's support for behavioural-specific disease management is assessed: proximal support e.g. friend and family and distal factor e.g. neighbourhood or community.</p>
	<p>Modified Medical Interview Satisfaction Scale (MISS-21)³⁸</p> <p>MISS-21 is a questionnaire to measure patient satisfaction with patient and health care professional communication/consultation.</p>

231

232 Data collection and follow-up

233 Each participant will be involved in the study for 12 months after taking consent and baseline
 234 data. The trial is expected to start January 2020 and finish October 2021.

235

236 Data collection methods will include:

- 237 a) Questionnaires: Questionnaire data will be collected face-to-face by research assistants for the
 238 full sample at baseline, 6 and 12 months at the community primary care unit where participants
 239 are recruited. A custom-designed form linked to RedCap will be used to collect, validate, verify,

240 and store respondents' data where possible or else data will be collected via paper forms and
241 double-entered into the databases. All data files and databases will be password protected.

242
243 b) Biological samples: Blood samples will be collected at baseline, 6 and 12 months, to measure
244 fasting blood glucose, HbA1c and lipids, coordinating where possible with the annual routine
245 tests offered to patients to reduce duplication. All blood samples will be administered from
246 participants by trained phlebotomists. Data will be linked to the participant information using a
247 unique respondent ID, which will be assigned to all study participants.

248
249 c) Interviews: During the delivery of the intervention, a process evaluation using a subset of
250 participants will be conducted using in-depth interviews and focus group discussions. These will
251 be audio-recorded. Data will be collected using a range of qualitative methods: a) one-to-one
252 interviews, and focus group discussions with nurses, health volunteers, people with diabetes and
253 their carers (5-10 focus groups, and 20 semi-structured interviews) and b) ethnography through
254 direct observations including video recordings of intervention delivery, and unstructured
255 interviews with clinical managers and policy makers. The data collected will be used to capture
256 the range of experiences of the intervention, and identify unanticipated pathways to generate new
257 theories as well as exploring the scalability of the intervention.

258 259 **Trial follow-up appointments**

260 The research team will hold weekly briefings with the study coordinators to generate a list of
261 priority areas and loss to follow-up participant lists. Arrangements to follow-up participants who
262 have not turned up for their appointment will be made, with attempts to contact participants

263 through SMS, phone calls, or house visits. Participants will be declared lost to follow-up if they
264 do not show for a month and are untraceable.

265

266 **Data management**

267 A data collection protocol will be developed, and the study coordinator in Thailand will provide
268 training to fieldworkers before data collection commences. Validation will be performed on a
269 random sample of questionnaire data by crosschecking with clinic records. Any discrepancies
270 will be followed-up and addressed by field workers, re-contacting participants to clarify as
271 necessary. Using Redcap (<https://redcap.med.cmu.ac.th>), quantitative data will be entered
272 directly via a form with built-in data checks to minimise transcription errors (or where necessary
273 collected on paper and later double entered into the electronic form). Post entry checks will be
274 conducted by exploring the distribution, ranges, and outliers of each variable. All hospital
275 laboratories have their own internal quality assurance protocols and are also linked to a national
276 external quality assurance mechanism. Fieldworkers will be trained in qualitative methods and
277 an interview schedule will be devised.

279 **Statistical analysis**

280 1. Quantitative analysis

281 Available outcome data will be analysed on an intention-to-treat basis. Potential clustering of
282 outcomes (HbA1c at 12 months and CVD risk score at 12 months) at the level of community
283 primary care units will be accounted for using random intercept models. To improve precision of
284 the estimates, outcomes will be adjusted for their baseline values. In case of baseline imbalances

1
2
3 285 of relevant covariates (e.g. age, education level, body mass index), judged by statistical
4
5 286 significance at $p < 0.05$, we will conduct a secondary analysis adjusting for these covariates.
6
7

8 287

9 10 288 2. Qualitative analysis

11
12 289 Qualitative data from interviews, focus groups and direct observations be will transcribed and
13
14 290 analysed using NVivo software. The data will be analysed using a descriptive, phenomenological
15
16 291 approach to understand participants' experiences and interpret them within their respective
17
18 292 cultural contexts. Comparative analysis will compare and contrast these themes across
19
20 293 participants. Deviant cases will be actively sought throughout the analysis and emerging ideas
21
22 294 and themes modified in response. In addition, thematic analysis will be used to inform elements
23
24 295 of scalability and to produce a set of considerations in making decisions about the scalability of
25
26 296 the intervention.
27
28
29

30
31 297

32 33 298 3. Cost-effective analysis

34
35 299 Data for economic evaluation (resource usage and quality of life using EQ-5D) will be obtained
36
37 300 prospectively alongside the trial. We will aim to capture all health service contacts, as well as
38
39 301 out-of-pocket expenses and medication use. Educator training costs will be included, as well as
40
41 302 minimal intervention material costs (as most will be made available freely after the trial). Utility
42
43 303 values from EQ-5D will be derived using a Thai tariff. Incremental cost utility will be estimated
44
45 304 from the Thai health system and societal perspectives, to provide incremental cost-effectiveness
46
47 305 ratio and probability of being cost-effective at Thai government's willingness to pay threshold of
48
49 306 160,000 baht/QALY.
50
51
52

53
54 307
55
56
57
58
59
60

1
2
3 3084
5 3096
7
8 3109
10 311 **ETHICS AND DISSEMINATION**11
12 312 This study is to be conducted according to the international standards of Good Clinical Practice13
14 313 (International Conference on Harmonization guidelines), Declaration of Helsinki, and15
16 314 International Ethical Guidelines for Biomedical Research Involving Human Subjects, applicable17
18 315 national government regulations, and institutional research policies and procedures. All19
20 316 investigators received GCP training at the onset of the study. Ethical approval was obtained prior21
22 317 to commencement of the project from Chiang Mai University [No 326/2018] and the London23
24 318 School of Hygiene & Tropical Medicine [16113/RR/12850]. The study protocol, informed25
26 319 consent form, patient information sheet and other relevant information has been approved. Any27
28 320 future amendments of the protocol shall be submitted to and approved by the Institutional29
30 321 Review Board (IRB) before implementation.31
32 32233
34 323 **Trial monitoring and oversight**35
36 324 The role of the Trial Steering Committee (TSC) is to provide overall supervision of the trial. The37
38 325 TSC will meet every six months. The TSC will include experts in the field of DSME, health39
40 326 psychology and clinical trials, as well as an independent Chair.41
42 32743
44 328 **Dissemination**45
46 329 Research findings will be disseminated to scientific audiences at major conferences and47
48 330 published in high-impact, open-access scientific journals; planned publications include those on

1
2
3 331 intervention development, primary trial results, process evaluation, and health systems analysis,
4
5 332 at a minimum. This study is expected to have a major policy impact due to the close involvement
6
7 333 of a key policy maker in the project. Towards the end of the study a dedicated workshop will be
8
9 334 held with key governmental stakeholders to disseminate the recommended model for DSME
10
11 335 implementation in Thailand and encourage inclusion of a large-scale scientific evaluation into
12
13 336 any national implementation of the scheme.
14
15
16
17 337
18

19 338 **Contributors:** CA, SS, OQ, PACM, SK were involved in conception and trial design. CA, KP,
20
21 339 PACM and SK wrote the first draft of the trial design proposal. KR, WT, KH, KK were involved
22
23 340 in critical revision of the trial design proposal. All authors contributed to finalising the trial
24
25 341 protocol. CA, KP, IPN, CP, AH, NW were involved with preparation of the manuscript for
26
27 342 submission. All authors reviewed the manuscript and approved the manuscript for publication.
28
29
30
31 343

32 344 **Funding**

33
34
35 345 This study is supported by UK Medical Research Council (MRC) grant number
36
37 346 [MR/R020876/1] and the Thailand Research Fund (TRF) grant number [DBG6180007].
38
39

40 347

41 348 **Data availability**

42
43
44 349 Data will be shared upon reasonable request
45
46
47 350

48 351 **Patient and Public Involvement**

49
50
51 352 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or
52
53 353 dissemination plans of our research.
54
55
56
57
58
59

1
2
3 354 **Trial registration and version**
4

5 355 The trial has been registered (ClinicalTrials.gov ID NCT03938233 Version 3 last update January
6
7 356 18,2020)
8
9

10 357 **Trial sponsor**
11

12 358 This study is sponsored by London School of Hygiene & Tropical Medicine, Keppel Street,
13
14 359 London WC1E 7HT, UK [16113].
15
16

17 360 **Competing interests**
18

19 361 None declared
20
21

22 362 **Ethics approval**
23

24 363 The study has been approved by the Chiang Mai University Research Ethics Committee
25
26 364 [326/2018] and the London School of Hygiene & Tropical Medicine [16113/RR/12850].
27
28

29 365
30

31 366 **Figure 1 Legend:** Trial flow diagram
32

33 367
34

35 368 **REFERENCES**
36

- 37
38 369 1. Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature
39
40 370 review of the burden, costs, and outcomes. *Glob Health* 2013; 9: 11.
41
42 371 2. International Diabetes Federation. *IDF Diabetes Atlas Seventh Edition*. 2015.
43
44 372 3. Jiraporncharoen W, Pinyopornpanish K, Junjom K, et al. Exploring perceptions,
45
46 373 attitudes and beliefs of Thai patients with type 2 diabetes mellitus as they relate to
47
48 374 medication adherence at an out-patient primary care clinic in Chiang Mai, Thailand.
49
50 375 *BMC Family Practice* 2020;21(1):173. doi: 10.1186/s12875-020-01233-7
51
52
53
54
55
56
57
58
59
60

- 1
2
3 376 4. Effect of intensive blood-glucose control with metformin on complications in
4
5 377 overweight patients with type 2 diabetes (UKPDS 34). *The Lancet* 1998; 352: 854–
6
7 378 65.
- 8
9
10 379 5. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial
11
12 380 intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J*
13
14 381 *Med* 2003; 348: 383–93.
- 15
16
17 382 6. Rangsin R. An assessment of quality of care among patients diagnosed with type 2
18
19 383 diabetes and hypertension visiting hospitals of ministry of public health and Bangkok
20
21 384 Metropolitan Administration in Thailand. 2012.
- 22
23
24 385 7. Auemaneekul N, Chandanasotthi P, Rawiworrakul T, et al. Community partnership,
25
26 386 context-based intervention and diabetes control in Thailand. *J Public Health* 2016;
27
28 387 46: 236–47.
- 29
30
31 388 8. Haas L, Maryniuk M, Beck J, et al. National standards for diabetes self-management
32
33 389 education and support. *Diabetes Educ* 2012; 38: 619–629.
- 34
35 390 9. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults
36
37 391 with type 2 diabetes mellitus: A systematic review of the effect on glycemic control.
38
39 392 *Patient Educ Couns* 2016; 99: 926–43.
- 40
41
42 393 10. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programmes for type 2 diabetes
43
44 394 mellitus: A systematic review and network meta-analysis. *Ann Intern Med* 2015;
45
46 395 163: 848.
- 47
48
49 396 11. Doyle G, O'Donnell S, Quigley E, et al. Patient level cost of diabetes self-
50
51 397 management education programmes: an international evaluation. *BMJ Open* 2017; 7:
52
53 398 e013805.
- 54
55
56
57
58
59
60

- 1
2
3 399 12. Fisher EB, Boothroyd RI, Elstad EA, et al. Peer support of complex health behaviors
4
5 400 in prevention and disease management with special reference to diabetes: Systematic
6
7 401 reviews. *Clin Diabetes Endocrinol* 2017; 3. DOI:10.1186/s40842-017-0042-3.
8
9
10 402 13. Dale JR, Williams SM, Bowyer V. What is the effect of peer support on diabetes
11
12 403 outcomes in adults? A systematic review. *Diabet Med* 2012; 29: 1361–77.
13
14
15 404 14. Norris SL, Chowdhury FM, Van Le K, et al. Effectiveness of community health
16 405 workers in the care of persons with diabetes. *Diabet Med J Br Diabet Assoc* 2006;
17
18 406 23: 544–56.
19
20 407
21
22 408 15. World Health Organization. Peer support programmes in diabetes: report of a WHO
23
24 409 consultation 5-7 November 2007. Geneva, Switzerland: WHO, 2008.
25
26
27 410 16. Fisher EB, Boothroyd RI, Coufal MM, et al. Peer support for self-management of
28
29 411 diabetes improved outcomes in international settings. *Health Aff (Millwood)* 2012;
30
31 412 31: 130–9.
32
33
34 413 17. Trento M, Gamba S, Gentile L, et al. Rethink Organization to iMprove Education
35
36 414 and Outcomes (ROMEIO): A multicenter randomized trial of lifestyle intervention by
37
38 415 group care to manage type 2 diabetes. *Diabetes Care* 2010; 33: 745–7.
39
40
41 416 18. Werfalli M, Raubenheimer P, Engel M, et al. Effectiveness of community-based
42
43 417 peer-led diabetes self-management programme (COMP-DSMP) for improving
44
45 418 clinical outcomes and quality of life of adults with diabetes in primary care settings
46
47 419 in low and middle-income countries (LMIC): A systematic review and meta-analysis.
48
49 420
50 420 BMJ Open 2015; 5: e007635.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 421 19. Keeratiyutawong P, Hanucharurnkl S, Melkus G, Vorapongsathon OPT.
4
5 422 Effectiveness of a self-management programme for Thais with type 2 diabetes. Thai
6
7 423 J Nurs Res 2006; 10: 85–97.
8
9
10 424 20. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
11
12 425 evaluating complex interventions: the new Medical Research Council guidance. BMJ
13
14 426 2008; a1655.
15
16
17 427 21. Wattana C, Srisuphan W, Pothiban L, Upchurch SL. Effects of a diabetes self-
18
19 428 management programme on glycaemic control, coronary heart disease risk, and
20
21 429 quality of life among Thai patients with type 2 diabetes. Nurs Health Sci 2007; 9:
22
23 430 135–41.
24
25
26 431 22. Wan EYF, Fung CSC, Wong CKH, Chin WY, Lam CLK. Association of
27
28 432 hemoglobin A1c levels with cardiovascular disease and mortality in Chinese patients
29
30 433 with diabetes
31
32
33 434 23. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self-
34
35 435 management programme (DESMOND) for people with newly diagnosed type 2
36
37 436 diabetes mellitus: Three-year follow-up of a cluster randomised controlled trial in
38
39 437 primary care. BMJ 2012; 344: e2333–e2333.
40
41
42 438 24. Tuong W, Larsen ER, Armstrong AW. Videos to influence: A systematic review of
43
44 439 effectiveness of video-based education in modifying health behaviors. J Behav Med
45
46 440 2014; 37: 218–33.
47
48
49 441 25. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions:
50
51 442 Medical Research Council guidance. BMJ 2015; 350: h1258–h1258.
52
53
54
55
56
57
58
59
60

- 1
2
3 443 26. Kimman M, et al. Validity of the Thai EQ-5D in an occupational population in
4
5 444 Thailand. *Qual Life Res* 2013 Aug; 22(6):1499-506.
6
7
8 445 27. Clinical Practice Guidelines for Diabetes. Diabetes Association of Thailand, 2017.
9
10 446 ([https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-
13
14 448 28. Aekplakorn A, Bunnag P, Woodward M. et al. Risk score for predicting incident
15
16 449 diabetes in the Thai population. *Diabetes Care* 2006 Aug; 29\(8\):1872-1877
17
18
19 450 29. Mahatnirunkul S, Tuntipivanaskul W, Pumpisanchai W, et al. Comparison of the
20
21 451 WHOQOL-100 and the WHOQOL-BREF. *Journal of Mental Health of Thailand*
22
23 452 1998; 5: 4-15.
24
25
26 453 30. Nilchaikovit T. et al. Development of Thai version of hospital anxiety and depression
27
28 454 scale in cancer patients. *J Psychiatr Assoc Thailand* 1996; 41\(1\):18-30.
29
30
31 455 31. Wongpakaran N, Wongpakaran T. The Thai version of the PSS-10: An investigation
32
33 456 of its psychometric properties. *BioPsychoSocial Medicine* 2010: 4:6
34
35 457 32. Rattanawiwatpong P, et al. Validity and reliability of the Thai version of Short
36
37 458 Format International Physical Activity Questionnaire \(IPAQ\). *J Thai Rehabil* 2006;
38
39 459 16\(3\):147-160.
40
41
42 460 33. Leelacharas S, et al. Illness perceptions, lifestyle behaviours, social support and
43
44 461 cardiovascular risks in people with Hypertension in Urban and Rural Areas of
45
46 462 Thailand. *Pacific Rim Int J Nur Res* 2015; 19
47
48
49 463 34. Lamsumang, W. The development of the Thai version of the diabetes management
50
51 464 self-efficacy scale \(T-DMSES\) for older adults with type 2 diabetes. State University
52
53 465 of New York at Buffalo, New York; 2009.
54
55
56
57
58
59](https://www.dmthai.org/index.php/knowledge/healthcare-providers/cpg/443-
11
12 447 guideline-diabetes-care-2017)

- 1
2
3 466 35. Sangruangake M, Jirapornkul C, Hurst C. Psychometric properties of diabetes
4
5 467 management self-efficacy in Thai type 2 diabetes mellitus patients: A multicenter
6
7 468 study. *Int J Endocrinol*. 2017;2017:2503156. doi:10.1155/2017/2503156)
8
9
10 469 36. Keeratiyatawong, P, Hanucharumkul, S., Melkus, G. D. E., Panpakdee, O.,
11
12 470 Vorapongsathorn T. Effectiveness of a self-management programme for Thais with
13
14 471 type 2 diabetes. *Thai J Nurse Res*. 2006; 10: 85-97
15
16
17 472 37. Manit A, et al. Development of needs and resources for self-management assessment
18
19 473 instrument in Thais with type 2 diabetes: Cross-cultural adaptation. *J Med Assoc*
20
21 474 *Thai* 2011; Vol. 94 No. 11.
22
23
24 475 38. Meakin R and Weinman J. The 'Medical Interview Satisfaction Scale' (MISS-21)
25
26 476 adapted for British general practice. *Family Practice* 2002; 19:257–263.
27
28
29 477

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Trial flow diagram
27x20mm (1200 x 1200 DPI)



Participant Information Sheet

Title of Project: Delivering Diabetes Self-Management Education in Thailand

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

The London School of Hygiene and Tropical Medicine (LSHTM) are conducting research for people with type 2 diabetes in Chiang Mai Thailand who have recently been diagnosed. The purpose of this study is to provide diabetes self-management education (DSME) by trained nurses and peer health care volunteers for those recently diagnosed.

This is a 3 arm cluster randomised trial where your service provider has been randomised to one of the following 3 interventions: 1) usual treatment 2) Nurse led DSME 3) Peer led DSME.

Why have I been asked to take part?

You have been invited because your healthcare provider is involved in the study and has identified you as being newly diagnosed with type 2 diabetes.

Do I have to take part?

No. It is up to you to decide to take part or not. If you don't want to take part, that's ok. Your doctor will still care for you and your decision will not affect the quality of care you receive.

We will discuss the study together and give you a copy of this information sheet. If you agree to take part, we will then ask you to sign a consent form.

What will happen to me if I take part?

Enrolling you in the study

If you are interested in taking part the research assistant will go through the information sheet with you. If you are happy with the information provided you may complete the consent form.

At this point you will also have the opportunity to raise with the researcher any questions you might have about the study. You do not have to enter the study unless you feel completely happy with what you are being asked to do.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 1 of 5



Participating in a diabetes education programme

You will be invited to attend a diabetes self-management educational programme. This programme will consist of a number of sessions delivered as monthly meetings led by community health volunteers or nurses. Short films about living with diabetes will be shown to introduce key topics.

The education and skills training will be followed by an open discussion session to discuss common challenges and solutions, set lifestyle goals and seek advice.

Collecting information

If you are happy to proceed with the study the researcher will then ask a series of questions relating to your health. This will be through completing a questionnaire booklet. These baseline questions will take about twenty minutes to complete. We will also take blood samples as the beginning of the study from trained phlebotomists.

Each participant will be compensated 200 baht for each of the baseline, 6 month and 12 month visit.

Follow up

Six months and twelve months after you have entered the study we will contact you again to ask you a further set of questions and blood samples to see how you are feeling now.

How is taking part in the study different from usual care?

Additional support and education may be provided through the study through the self-management education programme.

Whilst you are taking part in the study you will continue to be looked after by your healthcare providers, as normal. No treatment will be withheld from you during the course of this study.

The researcher will want you to complete some questionnaires at the beginning of the study and after six and twelve months. You may be asked to take part in an interview with a researcher.

What are the possible risks and disadvantages?

It will take some time to complete the questionnaire, around twenty minutes to complete. If you agree to be further interviewed, then this will also mean time will be needed to attend the interview. You may find minor discomfort from the taking blood samples. We will have trained phlebotomists to take the blood sample.

What are the possible benefits?

We cannot promise the study will help you but the information we get from the study will help our knowledge and understanding of this research area within diabetes self-management education in Thailand.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 2 of 5



What if something goes wrong?

If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions <+66(0)616852307>. If you remain unhappy and wish to complain formally, you can do this by contacting <if LSHTM is the sponsor: Patricia Henley at rgio@lshtm.ac.uk or +44 (0) 20 7927 2626>

The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you may be eligible to claim compensation.

Can I change my mind about taking part?

Yes. You can withdraw from the study at any time. You just need to tell your doctor that you don't want to be in the study anymore. Your doctor will still care for you.

If you withdraw from the study we will destroy all your identifiable samples/ tape recorded interviews, but we will need to use the data collected on you up to your withdrawal

Or

You can withdraw from treatment but keep in contact with us to let us know your progress. Information collected may still be used. Any stored blood or tissue samples that can still be identified as yours will be destroyed if you wish, or will continue to be stored for further research.

What will happen to information collected about me?

All information collected about you will be kept private. Only the study staff and authorities who check that the study is being carried out properly will be allowed to look at information about you. Data may be sent to other study staff in London or in Chiang Mai but this will be anonymised. This means that any information about you which leaves the hospital, will have your name and address removed so that you cannot be recognised.

Your doctor will send some details about you to the study team in Chiang Mai University who will store it securely. Your personal details will be kept in a different safe place to the other study information and will be destroyed within 10 years of the end of the study.

At the end of the project, the study data will be archived at Chiang Mai University. The data will be made available to other researchers worldwide for research and to improve medical knowledge and patient care. Your personal information will not be included and there is no way that you can be identified.

What will happen to the results of this study?

The study results will be published in a medical journal so that other doctors can learn from them. Your personal information will not be included in the study report and there is no way that you can be identified from it.

Who is organising and funding this study?

London School of Hygiene & Tropical Medicine is the sponsor for the research and they have full responsibility for the project including the collection, storage and analysis of your data.

This study is funded by the Medical Research Council UK and The Thailand Research Fund

Who has checked this study?

All research involving human participants is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by The London

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 3 of 5



School of Hygiene and Tropical Medicine Research Ethics Committee (<ref: 16113>). The Research Ethics Committee, Faculty of Medicine, Chiang Mai University (No 326/2018) has also reviewed the study and have agreed that it is okay for us to ask people to take part.

Further information and contact details

Thank you for taking time to read this information leaflet. If you think you will take part in the study please read and sign the consent form.

If you would like any further information, please contact Dr. Chaisiri Angkurawaranon, MD, who can answer any questions you may have about the study.

Contact details: Chaisiri Angkurawaranon, Department of Family Medicine, Faculty of Medicine, Chiang Mai University. Tel +66(0)616852307, Email: chaisiri.a@cmu.ac.th

What happens if new information becomes available during the study?

Sometimes during a study, new information becomes available about the treatment being studied. If this happens, the research team will tell you and discuss whether you want to continue in the study. If you decide to stop taking part in the study your usual care will continue. If you decide to continue in the study you may be asked to sign an updated consent form. If we think you should withdraw from the study, we will explain the reasons and arrange for your care to continue.

What happens when the study stops?

Very occasionally a study is stopped early. If this happens, the reasons will be explained to you.

Tissue studies:

What will happen to the samples I give?

Blood samples will be used to measure HbA1c and lipids, coordinating where possible with the annual routine tests offered to patients to reduce duplication. Blood will be drawn by a trained phlebotomist when participants come for interview and sent to laboratory for analysis. Data will be linked to the participant information using a unique respondent ID, which will be assigned to all study participants.

Blood samples will be sent to a laboratory within the Chiang Mai area. The results of the blood tests will be provided to your health care professional who will discuss with you if there are any issues.

We may use some of the samples collected for future studies. These will be anonymised when stored, and all future research using these samples will be reviewed by an independent ethics committee.

A copy of this informed consent document to be offered to the participant

Study title: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Version & Date: V0.1 08/10/2018

Principal Investigator: Sanja Kinra

REC ref:

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 4 of 5

CONSENT FORM FOR PARTICIPANT AND REPRESENTATIVE

Title of Project: A scalable solution for delivery of Diabetes Self-Management Education in Thailand

Name of PI/Researcher responsible for project: Chaisiri Angkurawaranon

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statement	Please initial or thumbprint* each box
I confirm that I have read and understood the information sheet dated 08.10.2018 (version 1.0) for the above named study. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.	
I understand that my consent is voluntary and that I am free to withdraw this consent at any time without giving any reason and without my medical care or legal rights being affected.	
I understand that relevant sections of my/the participant's medical notes and data collected during the study may be looked at by authorised individuals from Chiang Mai University, where it is relevant to my taking part in this research. I give permission for these individuals to have access to these records.	
I understand that data about/from me/the participant may be shared via a public data repository or by sharing directly with other researchers, and that I will not be identifiable from this information	
I understand that the tissue sample collected from me will be used to support other research in the future, and may be shared anonymously with other researchers, for their ethically-approved projects	
I give permission for a copy of this consent form, which contains my personal information, to be made available to the Trial Coordinating Centre for monitoring purposes only.	
I agree to my health care provider being informed of my participation in the study.	
I agree to me taking part in the above named study.	

--	--	--

Printed name of participant/Representative Signature of participant/Representative Date
(or thumbprint/mark if unable to sign)

--	--	--

Printed name of person obtaining consent Signature of person obtaining consent Date

The participant is unable to sign. As a witness, I confirm that all the information about the trial was given and the participant/representative consented to taking part *(*only required if the participant/representative is unable to read or write)*

--	--	--

Printed name of impartial witness* Signature of impartial witness* Date

A copy of this informed consent document has been provided to the participant.

Centre Number:
Study Number:
Participant Identification Number:

แบบขอรับความยินยอมเข้าร่วมโครงการ (Consent ข้อมูลสำหรับผู้ป่วย)

ชื่อโครงการศึกษาวิจัย : “การพัฒนาทางออกเพื่อการขยายการบริการที่เพิ่มความสามารถในการดูแลตนเองของผู้ที่เป็นเบาหวานในประเทศไทย”

หมายเลขโครงการศึกษาวิจัย : FAM-2561-05594

ผู้ให้ทุนสนับสนุนการวิจัย : สำนักงานคณะกรรมการส่งเสริมวิทยาศาสตร์ วิจัยและนวัตกรรม (สกสว.)

แพทย์ผู้วิจัยหลัก : อ.ดร.นพ.ชัยสิริ อังกระวรรณนท์

ท่านได้รับการเชิญให้เข้าร่วมการศึกษานี้เนื่องจากท่านได้รับการวินิจฉัยว่าเป็นโรคเบาหวานที่เพิ่งได้รับการวินิจฉัยมาไม่เกิน 1 ปี หรือเป็นผู้ป่วยเบาหวานที่ยังไม่สามารถควบคุมน้ำตาลได้ ขอให้ท่านกรุณาอ่านข้อมูลข้างล่างก่อน (หรือผู้วิจัยได้อ่านให้ท่านรับทราบ) หากท่านมีข้อข้องใจใดๆ เกี่ยวกับการศึกษานี้ และสิทธิของท่าน กรุณาซักถามจากแพทย์ผู้ทำการศึกษานี้ หรือ ผู้ช่วยแพทย์ที่ทำการศึกษานี้ ซึ่งจะเป็นผู้สามารถให้ความกระจ่างแก่ท่านได้ หากท่านตัดสินใจเข้าร่วมการศึกษานี้ ท่านจะได้รับเอกสารข้อมูลสำหรับผู้เข้าร่วมโครงการวิจัยและสำเนาใบยินยอมที่ท่านเซ็นชื่อกำกับเก็บไว้ 1 ฉบับ

การศึกษานี้เกี่ยวกับเรื่องอะไร

เนื่องจากในปัจจุบันนี้มีผู้ป่วยเป็นโรคเบาหวานจำนวนมากขึ้น และพบว่าผู้ป่วยเป็นโรคเบาหวานนี้สัมพันธ์กับภาวะแทรกซ้อนทางสุขภาพมากมาย เพื่อให้เป็นประโยชน์ต่อการพัฒนาการดูแลรักษาผู้ป่วยเบาหวานในอนาคต ผู้วิจัยจึงสนใจที่จะศึกษาว่าการเป็นโรคเบาหวานนั้นสัมพันธ์กับการเปลี่ยนแปลงระดับชีวภาพในร่างกายอย่างไร โดยผ่านการตรวจเลือดและอุจจาระ และเพื่อศึกษาว่าการจัดทำโครงการให้ความรู้ในการดูแลตนเองของผู้ป่วยเบาหวานโดยใช้สื่อมัลติมีเดียเข้าช่วยเหลือมีผลลัพธ์ของการรักษาที่ดีขึ้นได้หรือไม่ การศึกษานี้จะรวบรวมผู้ป่วยประมาณ 600 ราย จากโรงพยาบาลชุมชนที่ให้การรักษาระบบปฐมภูมิ ในจังหวัดเชียงใหม่ และ ลำปาง

ท่านจะต้องปฏิบัติตัวอย่างไร

หากท่านตัดสินใจเข้าร่วมการศึกษานี้ท่านจะถูกขอร้องให้เซ็นชื่อลงในใบยินยอมท่านจะได้รับการซักประวัติเกี่ยวกับโรคประจำตัวและการรักษาที่ได้รับ ได้ตรวจร่างกาย และการเจาะเลือด

เพื่อเป็นข้อมูลเริ่มต้นก่อนการรักษา โดยทั้งนี้ท่านจะได้รับการดูแลตามปกติควบคู่ไป

จากนั้นท่านจะได้รับการอบรมเพื่อพัฒนาศักยภาพในการดูแลตนเองในโรคเบาหวานของท่านโดยทีมดูแลสุขภาพ ซึ่งหน่วยบริการของท่านจะถูกสุ่มให้อยู่ 1 ใน 3 กลุ่ม อันได้แก่ กลุ่มทดลอง1 กลุ่มทดลอง2 และกลุ่มควบคุม โดยทั้ง 3 กลุ่มจะได้รับข้อมูลและการดูแลพื้นฐานเช่นเดียวกัน แต่แตกต่างกันในรูปแบบของการให้การอบรมในการดูแลตนเองของผู้ป่วยเบาหวาน ซึ่งจะใช้เวลาไม่นาน ไม่เกิน ครึ่งวัน โดย

- กลุ่มที่1 อบรมโดยบุคลากรทางการแพทย์ พยาบาล หรือ เจ้าหน้าที่สาธารณสุข
- กลุ่มที่2 อบรมโดยกลุ่มเพื่อนช่วยเพื่อนหรืออสม.ที่ผ่านการฝึกอบรมด้านการเพิ่มศักยภาพในการดูแลตนเองในโรคเบาหวาน
- กลุ่มที่ 3 ได้รับความรู้จากการดูแลตามมาตรฐานของกระทรวงสาธารณสุข

ซึ่งทั้งสามกลุ่ม จะมีการนัด หรือ ติดตาม ความก้าวหน้าพฤติกรรม的自我ดูแลตนเอง ทุกๆ 1-3 เดือน

การติดตามผลเลือดและตอบแบบสอบถาม จะถูกทำในครั้งแรกข้างต้น และอีก 2 ครั้ง คือ ที่ 6 เดือนและที่ 12 เดือนนับจากครั้งแรกที่อบรม โดยทั้ง 3 ครั้ง ท่านจะถูกเจาะเลือดเพื่อส่งตรวจปริมาตรทั้งสิ้นครั้งละ 40 มิลลิลิตร

ความเสี่ยงจากการเข้าร่วมการวิจัยนี้

ความเสี่ยงจากการเจาะเลือด - ท่านอาจรู้สึกหน้ามืด เป็นลม ปวดบริเวณที่เจาะ หรือมีจ้ำเลือดบริเวณที่เจาะ มีความเสี่ยงน้อยมากที่จะเกิดการติดเชื้อจากการเจาะเลือดเพราะเราใช้เข็มเจาะเลือดที่ปราศจากเชื้อและใช้ครั้งเดียวทิ้ง การเจาะเลือดทั้งหมดอยู่ในสถานพยาบาล และหากมีปัญหาจะได้รับการดูแลทันที

ท่านจะได้ประโยชน์อะไรจากการศึกษา

ท่านจะได้รับความรู้เพื่อนำไปใช้ในการดูแลตนเองเพื่อควบคุมโรคเบาหวานของท่าน และผลสรุปที่ได้จากการศึกษานี้จะเป็นประโยชน์ต่อผู้ป่วยรายอื่นในอนาคต

ค่าใช้จ่ายในการเข้าร่วมวิจัย

ท่านจะไม่ต้องเสียค่าใช้จ่ายเพิ่มเติมเกี่ยวกับการวิจัยนอกเหนือจากค่ารักษาปกติที่ควรจะเป็นซึ่งท่านสามารถใช้สิทธิในการเบิกจ่ายได้ตามสิทธิการรักษาปกติของท่าน

ค่าตอบแทน

สำหรับการมาตรวจติดตามที่เพิ่มจากการตรวจรักษาตามปกติ จำนวน 5 ครั้ง ซึ่งจะมีการตรวจเลือด รวม 3 ครั้ง ท่านจะได้รับค่าเดินทางและค่าเสียเวลาครั้งละ 100 บาท (รวม 500 บาทต่อคน ตลอดระยะเวลาโครงการ 1 ปี)

หากท่านได้รับบาดเจ็บจากการเข้าร่วมการศึกษาวิจัย

หากท่านได้ปฏิบัติตามคำแนะนำของแพทย์ผู้วิจัยแล้ว กระบวนการต่าง ๆ ในการวิจัยทำให้ท่านได้รับบาดเจ็บ เมื่อผู้วิจัยได้รับแจ้งจากท่าน ท่านจะได้รับการส่งต่อเพื่อรักษาภาวะดังกล่าวทันที

ท่านจะอย่างไรหากท่านไม่ต้องการเข้าร่วมการศึกษาวิจัย หรือเปลี่ยนใจระหว่างร่วมศึกษาวิจัย

ท่านไม่จำเป็นต้องเข้าร่วมการศึกษาวิจัยนี้หากท่านไม่สมัครใจ หลังจากท่านตัดสินใจจะเข้าร่วมการศึกษาแล้ว ท่านสามารถจะถอนตัวได้ตลอดเวลา การตัดสินใจของท่านจะไม่มีผลต่อการรักษาในอนาคต หรือการดูแลอื่นใดหากท่านไม่ต้องการเข้าร่วมการศึกษาหรือต้องการหยุดการศึกษา ณ เวลาใดก็ตาม แพทย์ของท่านจะอธิบายให้ทราบถึงการรักษาอื่น ๆ ซึ่งเป็นทางเลือกที่มีอยู่ขณะนี้ ผู้วิจัยอาจจะตัดสินใจยกเลิกท่านจากการศึกษา หากเห็นว่าจะเป็นประโยชน์สำหรับท่านมากกว่า

ใครจะรู้บ้างว่าท่านเข้าร่วมการศึกษานี้

แพทย์ประจำตัวท่าน (แพทย์เวชปฏิบัติทั่วไป) ควรจะได้รับทราบว่าท่านตัดสินใจเข้าร่วมการศึกษาวิจัยนี้ ข้อมูลของท่านที่ถูกบันทึกไว้ระหว่างการศึกษานี้ เช่นเดียวกับข้อมูลที่เกี่ยวข้องจากแฟ้มเวชระเบียนของโรงพยาบาล คลินิก บริษัทฯ หรือข้อมูลอื่น ๆ จะถูกเก็บไว้เป็นความลับตลอดเวลา คณะกรรมการจริยธรรมการวิจัยสามารถที่จะขอตรวจสอบข้อมูลเหล่านี้ได้ โดยข้อมูลเหล่านี้จะยังเก็บรักษาไว้เป็นเรื่องลับเฉพาะ

การปกป้องรักษาข้อมูล : ข้อมูลใดบ้างที่จะถูกเก็บรวบรวมไว้จากการศึกษานี้

ข้อมูลที่ถูกเก็บรวบรวมนั้นจะมีเฉพาะในส่วนที่เกี่ยวข้องกับการศึกษาเพื่อวัตถุประสงค์ทางการวิจัยทางการแพทย์ โดยจะไม่มีการอ้างถึงข้อมูลส่วนตัวของท่าน อันได้แก่ชื่อท่าน ในรายงานหรือวารสารใด ๆ หากท่านตกลงใจเข้าร่วมการศึกษา ท่านยินยอมที่จะไม่จำกัดการให้ข้อมูลที่เป็นส่วนตัวยกเว้นในกรณีที่ขัดต่อสิทธิส่วนบุคคลภายใต้กฎหมายคุ้มครองสิทธิส่วนบุคคล

หากท่านมีคำถามเกี่ยวกับการศึกษานี้ท่านสามารถติดต่อใครได้บ้าง

หากท่านมีคำถามหรือมีความวิตกกังวลเกี่ยวกับการศึกษาวิจัยนี้ หรือสงสัยว่าท่านกำลังได้รับบาดเจ็บจากการเข้าร่วมการวิจัยนี้ กรุณาติดต่อ คุณกุลฎาภา อยู่นัด ได้ที่ ภาควิชาเวชศาสตร์ครอบครัว โทรศัพท์ที่ทำงาน 053-936362 (ในเวลาราชการ)

ส่วนแสดงความยินยอม

โดยการลงนามในหนังสือยินยอมฉบับนี้ ท่านยอมรับว่าได้อ่านเอกสารฉบับนี้แล้วและได้รับคำอธิบายเกี่ยวกับการศึกษาวิจัยนี้ รวมถึงได้รับคำตอบเกี่ยวกับข้อสงสัยต่าง ๆ ที่ท่านมีจากผู้วิจัยแล้ว

1
2
3
4
5 ท่านตกลงใจที่จะเข้าร่วมในการศึกษาวิจัยนี้ และมีสิทธิ์ที่จะถอนตัวจากการศึกษาวิจัยนี้ได้ทุกเมื่อ โดยไม่มี
6 ผลต่อการรักษาในอนาคต โดยการลงนามนี้ท่านไม่ได้สละสิทธิ์ใด ๆ ที่พึงมีทางกฎหมาย
7
8 ทั้งนี้ ท่านยินยอมที่จะเข้ารับการอบรมในโครงการวิจัย ตอบแบบสอบถามและ
9

10
11
12
13
14 ลายมือชื่ออาสาสมัคร _____ วัน-เดือน-ปี _____

15
16
17 (_____)

18
19
20 ลายมือชื่อเจ้าหน้าที่ผู้ให้ข้อมูล _____ วัน-เดือน-ปี _____

21
22 ณ สถานพยาบาล

23
24 (_____)

25
26 พยาน _____ วัน-เดือน-ปี _____

27
28
29 (_____)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	Page/Line number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Line 357
	2b	All items from the World Health Organization Trial Registration Data Set	-
Protocol version	3	Date and version identifier	Lines 357-358
Funding	4	Sources and types of financial, material, and other support	Lines 344-346
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page 1 and Lines 338-342
	5b	Name and contact information for the trial sponsor	Lines 359-360
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Lines 344-353

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Lines 322-326
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Page 4 and 5
	6b	Explanation for choice of comparators	Lines 99-103
Objectives	7	Specific objectives or hypotheses	Lines 92-94, 217-226
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Lines 98-103
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Lines 105-117
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Lines 119-129

Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Lines 157-187
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	n/a
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Lines 192-197
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Lines 217-229
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Page 9-11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Lines 140-148
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Lines 131-138
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	n/a
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial	
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Lines 228 Table 2
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Lines 264
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Lines 277-285
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Lines 277-285

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	n/a
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	Lines 322
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Lines 364

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Lines 319-320
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Lines 150-155
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Lines 150-155
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Lines 362-363
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Lines 348-349
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Lines 328-336
	31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Attached
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.